Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer

Biocon Limited, India’s pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy. ABRAXANE is now available in India as a single-use 100 mg vial (as a lyophilized powder, to be reconstituted for intravenous administration).

In October 2007, ABRAXANE was approved by the Drug Controller General of India. The approval was based on the clinical trial data that was the basis of approval in the United States. The Phase III clinical trial in the U.S. demonstrated that ABRAXANE nearly doubled the response rate, significantly prolonged time to progression, and significantly improved overall survival in the second-line setting versus solvent-based Taxol(R) in the approved indication.

In the U.S. pivotal head-to-head trial, the overall response rate of ABRAXANE was 33% vs. 19% compared to Taxol (P = .001), and ABRAXANE achieved a 25% percent improvement in time to tumor progression (23.0 weeks vs. 16.9 weeks; hazard ratio = 0.75; P = .006) when compared to Taxol. Furthermore, patients receiving ABRAXANE in the second-line setting had a significantly prolonged survival by an additional 27% compared to solvent-based Taxol (56.4 weeks vs. 46.7 weeks; P = 0.24). The tolerability with ABRAXANE and Taxol was comparable, despite the 50% greater dose of paclitaxel administered as ABRAXANE.

“The launch of ABRAXANE in India represents a major strategic step in our plan to provide safer and more effective cancer treatments on a global scale,” said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience. “In addition to India, our marketing agreement with Biocon covers more than ten countries, and we are working closely with national authorities throughout the region to receive regulatory approvals and commence marketing activities as soon as practicable.”

“This launch provides breakthrough therapeutics to cancer patients in India,” said Kiran Mazumdar-Shaw, Chairman & Managing Director of Biocon. “ABRAXANE is a significant advance in taxane therapy for the treatment of breast cancer. This unique product eliminates the need for chemical solvents and allows for higher doses of paclitaxel without compromising safety and tolerability. The launch of ABRAXANE reiterates our belief in strategic licensing partnerships to advance therapeutics in India, and we take great pride in providing oncologists in India with the latest treatment in breast cancer.”

Ms. Mazumdar-Shaw noted that ABRAXANE is an important addition to Biocon’s Oncotherapeutics portfolio, which has already seen the successful launch of its proprietary antibody, BIOMAb EGFR(TM) for the treatment of head and neck cancers.

Neil Desai, Ph.D., Vice President of Research and Development at Abraxis BioScience, said, “ABRAXANE is the first nanotechnology based anti-cancer drug that is administered as albumin-bound particles of approximately 130 nanometers and takes advantage of albumin, a natural protein that acts as the body’s key transporter of nutrients and other water-insoluble molecules and accumulates in tumor tissues. The drug has demonstrated superiority in progression free survival over both Taxol(R) Injection and Taxotere(R) Injection in recent randomized clinical trials. The initial clinical trials for ABRAXANE were conducted in India and we are very satisfied to be able to bring this drug to the Indian patients through our partner Biocon.”

Rakesh Bamzai, President – Marketing, Biocon, said, “Presently, more than 100,000 new cases of breast cancer occur in Indian women every year. Breast cancer is the second largest cause of death among women diagnosed with cancer in India. With the launch of ABRAXANE through Biocon’s innovation led Oncotherapeutics division and the growing need for this drug in the country, we look forward to attaining market leadership in this segment.”

Cancer rates in India are lower than those seen in Western countries, but are rising with increasing migration of rural population to the cities, increasing life expectancy and changing lifestyles. The breast is the second most common site of cancer in women after the cervix uteri. In the metropolitan cities of New Delhi and Mumbai, it is the most common kind of cancer in women. The annual age-adjusted rate (AAR) varies between the urban and rural areas. In the urban areas, the AAR is 21.9 to 28.3 per 100,000, whereas in rural areas, it is 8.6 per 100,000.

In August 2007, Abraxis established a licensing agreement with Biocon for the commercialization of ABRAXANE in India. Under the terms of the agreement, Biocon has the right to market ABRAXANE in India, Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Saudi Arabia, Kuwait and certain other South Asian and Persian Gulf countries. Subsequently, Abraxis received approval in October 2007 from India’s Drug Control General to market ABRAXANE in India.

ABRAXANE is approved for marketing in 35 countries. Abraxis has several pending patent applications in India relating to ABRAXANE.

In the Asia-Pacific region, ABRAXANE is approved for marketing in China and Korea in addition to India. ABRAXANE is under regulatory review for the treatment of breast cancer by the Therapeutic Goods Administration (TGA) in Australia, the Federal Authority for Healthcare and Social Development Regulation in Russia, and the Ministry of Health, Labour and Welfare in Japan.

About ABRAXANE(R)

ABRAXANE(R) is a solvent-free chemotherapy treatment option for metastatic breast cancer. Developed using Abraxis BioScience’s proprietary nab(TM) technology platform, ABRAXANE is a protein-bound chemotherapy agent, which combines paclitaxel with albumin, a naturally-occurring human protein, to deliver the drug and eliminate the need for solvents in the administration process. Because solvents are eliminated, ABRAXANE allows for the delivery of a 49% higher dose compared to solvent-based paclitaxel (Taxol(R)) without compromising safety and tolerability. ABRAXANE is administered in 30 minutes (as compared to three hours for solvent-based paclitaxel).

ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: first-line metastatic breast, non-small cell lung, malignant melanoma, pancreatic, and gastric. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis and renal dysfunction. For the full prescribing information for ABRAXANE, including Boxed Warning, please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience and is marketed in the United States under a co-promotion agreement between Abraxis and AstraZeneca.

About Biocon Limited

Biocon Limited is India’s pioneer biotechnology enterprise established in 1978. Biocon and its two subsidiaries, Syngene and Clinigene form a fully integrated biotechnology enterprise, with specialized focus on biopharmaceuticals, contract research and clinical research. Strategic international acquisitions, such as acquiring a majority in the German pharmaceutical company, AxiCorp, have given Biocon wider global access and greater market penetration. Many of our products have USFDA and EMEA acceptance.

Biocon’s proprietary technologies have been used effectively in diabetology, oncology, cardiology, nephrology and other therapeutic treatments. The company’s robust drug discovery pipeline offers novel therapies on a platform of affordable innovation. Biocon launched the world’s first recombinant human insulin, INSUGEN(R) in November 2004 using Pichia expression and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM) in September 2006. Visit the company at www.biocon.com

About Abraxis BioScience

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company’s portfolio includes the world’s first and only protein-bound chemotherapeutic compound (ABRAXANE), which is based on the company’s proprietary tumor targeting technology known as the nab(TM) platform. The first FDA approved product to use this nab(TM) platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

FORWARD-LOOKING STATEMENTS

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the launch of ABRAXANE in India. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, unexpected safety, efficacy or manufacturing issues with respect to ABRAXANE; the need for additional data or clinical studies for ABRAXANE; regulatory developments (domestic or foreign) involving the company’s manufacturing facilities; the market adoption and demand of ABRAXANE, the costs associated with the ongoing launch of ABRAXANE; the impact of pharmaceutical industry regulation; the impact of competitive products and pricing; the availability and pricing of ingredients used in the manufacture of pharmaceutical products; the ability to successfully manufacture products in a time-sensitive and cost effective manner; the acceptance and demand of new pharmaceutical products; and the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2007 and in other documents it has filed with the Securities and Exchange Commission.

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.

Taxol(R) is a registered trademark of Bristol-Myers Squibb Company.

Taxotere(R) is a registered trademark of Sanofi-Aventis.

Gold’s Gym Works Out

By JEFF POSTELWAIT

The doors have opened at Tulsa’s only Gold’s Gym, and its ownership says that not only is the facility unique for the metro area, it’s also a new design and layout for the fitness chain.

The 52,000-square-foot gym was built in the former location of a Mervyn’s department store at 6612 S. Memorial Drive, along with several other businesses.

The gym’s unique feature is its Cardio Cinema room, in which about 40 people at a time can work out on treadmills while watching movies on a large projection screen in a movie-theater inspired setting, said Joanna Barber, a spokeswoman for Dallas-based Gold’s Gym International Inc.

A grand opening is being held Saturday.

General Manager Noe Lozano said Gold’s Gym is one of the most recognized fitness brands in the country, adding that Gold’s Gym products will be available at the facility.

“What people like about Gold’s Gym is the brand,” Lozano said. “When people walk in, they know the brand.”

The gym’s location near Woodland Hills Mall has already made it popular with Tulsans, Lozano said, adding that it has sold about 1,800 memberships since the beginning of the year.

“One of the things Gold’s Gym tries to do is move into a part of town where we can make a big impact. The location itself is beautiful,” he said.

Lozano estimated that the gym could sign up as many as 5,000 members by the end of the year.

The facility itself can accommodate as many as 800 people at once, he said.

Special amenities include a women-only workout area, private locker rooms and showers, a large group aerobics studio and a separate yoga and pilates studio.

Members can purchase the services of specialized personal trainers who are nationally accredited and certified in their area of workout expertise, Lozano said. The trainers will offer about 40 classes per week.

The new facility is not Tulsa’s first Gold’s Gym, but it’s the only one still open. Another location, at 5899 S. Garnett Road, closed years ago, Barber said.

A second Tulsa-area Gold’s Gym will be developed in Broken Arrow as part of a 72,700-square-foot retail development at Kenosha Street and Aspen Avenue.

“That will be opened early next year,” Lozano said.

Gold’s Gym’s parent company is Irving, Texas-based Omni Hotels. The company owns more than 80 gyms in North America.

Features at Gold’s Gym

25 Life Fitness treadmills

25 Eliptical Trainers

25 Cybex Arc Trainers

The Cardio Cinema plays latest releases from Blockbuster in a movie setting with cardio equipment Three group class studios including a yoga studio

Lady Gold’s area, a private space for women, with cardio and weight equipment

25-meter lap pool

Jacuzzi spa & dry sauna

Core training and stretching area

Fresh smoothie bar

Full-size locker rooms for men and women

Complete line of Cypex, “Hammer Strength” and Life Fitness

Weight-training equipment as well as free weights

Jeff Postelwait 581-8387

jeff.postelwait@tulsaworld

Originally published by JEFF POSTELWAIT World Staff Writer.

(c) 2008 Tulsa World. Provided by ProQuest Information and Learning. All rights Reserved.

Speculation on Miller’s Ailment Can Serve As Diabetes Warning

By Heather May, The Salt Lake Tribune

Jul. 18–Diabetic patients rarely end up in the hospital for more than a month like Larry Miller. But the Jazz owner and business magnate’s poor health underscores the seriousness of a disease that continues to grow in Utah.

Since Miller was admitted to an unspecified hospital June 10, Miller’s family has not said what ails him but have attributed his stay to complications from diabetes. In announcing Miller’s hospitalization in June, his oldest son, Greg Miller, said his father was coherent and conversing, possibly ruling out a stroke.

The other most common reasons diabetics are hospitalized include cardiovascular disease, kidney failure, comas and amputations, according to state health department data.

“When diabetics end up in the hospital, if it’s in any way related to diabetes, it’s typically because they have very high blood sugars and very poor control,” said Jim Chamberlain, a diabetologist who specializes in poorly controlled diabetes at the University of Utah’s Diabetes Care Center.

He is not treating Miller and doesn’t know the details of his case. But he said a heart attack, stroke, limb amputation or serious infection could require extensive hospitalization and rehabilitation — which Miller is undergoing — depending on many factors including their health before the problem.

Doctors say diabetics can significantly reduce their risk of serious problems by keeping their diabetes under control though diet, exercise and sometimes medications and insulin shots.

“I tell my patients, ‘If you’re motivated and you want to take good care of yourself and you get the diabetes education you need, you can pretty much live a normal life,’ ” said Chamberlain, who noted more medications are coming to the market that manage glucose levels and help patients lose weight.

Miller’s diabetes management is unknown, but his son has told reporters his father is not “exactly a picture of health.” During Jazz games, he could be seen hobbling to his courtside seat.

“Unfortunately, he’s neglected himself for too long and now he’s paying the price for that,” Greg Miller told reporters in June. Most Utahns with diabetes don’t maintain proper glucose levels, said E. Dale Abel, chief of University Hospital’s division of endocrinology.

“It’s not impossible,” said Abel, who is not treating Miller, “but one has to work with the provider and modify one’s lifestyle.”

The state health department has found that many Utahns are not following the “gold standard” of diabetes control, which is getting at least two hemoglobin A1C exams each year. The exams measure the average level of glucose in the blood in the prior three months.

The percentage of diabetics who follow the recommendation recently see-sawed between about 70 percent and 55 percent.

Keeping glucose levels in check is critical because too much can damage the heart, blood vessels, eyes and kidneys, according to the National Diabetes Information Clearinghouse.

It also compromises the immune system and causes nerve damage, which can lead to serious infections and then amputations.

Greg Miller said his father “probably” kept the disease hidden for some time.

Advocates for diabetics say there is a stigma. Many hope Miller’s poor health will serve as a wake-up call to other diabetics and motivate them to regulate their glucose, blood pressure, cholesterol and weight and get regular foot and eye exams and get screened for kidney failure.

Mahtab Sohrevardi, medical director of Intermountain Medical Center’s Diabetic Care Center, said it also could spur Utahns without diabetes. She also is not treating Miller.

“It’s really important to have a very good diet, and exercise. Preventing diabetes is way easier than treatment.”

[email protected]

Diabetes in Utah

–Diabetes is a chronic metabolic disorder characterized by high levels of glucose in the blood due to the body’s inability to produce enough insulin or use it effectively. Larry Miller has Type 2 diabetes, which is typically brought on by obesity and aging.

–The percentage of Utahns diagnosed with diabetes has been steadily growing since the 1990s. About 104,000 Utahns, including children, have the disease, which is the sixth leading cause of death. About 8 percent of adults are affected.

—–

To see more of The Salt Lake Tribune, or to subscribe to the newspaper, go to http://www.sltrib.com.

Copyright (c) 2008, The Salt Lake Tribune

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Hall Family Pledges an Additional $11 Million to Children’s Mercy Hospital

By Alan Bavley, The Kansas City Star, Mo.

Jul. 18–Members of the Hall family plan to donate $11 million over three years toward Children’s Mercy Hospital’s $800 million expansion plan, the hospital announced Thursday.

The contribution is in addition to the $43 million already pledged for the project by the Hall Family Foundation, which was established with money from Hallmark Cards founder Joyce C. Hall and his wife, Elizabeth.

In December, Children’s Mercy announced the 15-year expansion plan, which will more than double the size of its complex on Hospital Hill and increase its presence in area suburbs.

The three-phase project, expected to take from 12 to 15 years, will add 216 inpatient beds to the Hospital Hill campus, for a total of 476. It also will add hundreds of thousands of square feet of new outpatient clinics, offices and clinical lab space.

The $43 million Hall gift will help pay for the $280 million first phase of the expansion, which will include an expanded emergency room, two new heart catheterization labs and an eight-story building for outpatient clinics and physician offices on Hospital Hill.

The $11 million gift is being made by Don and Adele Hall, Keith and Margi Pence, Donald and Jill Hall, David and Laura Hall and Barbara Hall Marshall.

| Alan Bavley, [email protected]

—–

To see more of The Kansas City Star, or to subscribe to the newspaper, go to http://www.kansascity.com.

Copyright (c) 2008, The Kansas City Star, Mo.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

The Cementite Spheroidization Process in High-Carbon Steels With Different Chromium Contents

By Luzginova, N V Zhao, L; Sietsma, J

The cementite spheroidization process is investigated in hypereutectoid steels with different chromium (Cr) contents. A spheroidized structure in high-carbon steel is usually obtained by a divorced eutectoid transformation (DET) reaction, which occurs during slow cooling of austenite with fine cementite particles. A bimodal distribution of spheroidized cementite particles is experimentally observed. It is shown that Cr addition allows one to obtain the spheroidized structure after austenitization at a higher temperature and a longer annealing time as compared with low-Cr steel. It is found that the DET reaction takes place at low undercoolings compared with the pearlitic reaction. The occurrence of the DET reaction also depends strongly on the spacing between cementite particles during the austenitization process, i.e., on austenitization temperature and time. DOI: 10.1007/s11661-007-9403- 3

(c) The Authors(s) 2008

I. INTRODUCTION

THE spheroidization annealing, which results in a microstructure of fine spherical cementite particles in a soft ferritic matrix,[1] is of significant interest for industrial applications. The main purpose of this process is to reduce the hardness of the material and thus provide a good machinability prior to further processing.[2] Two types of spheroidization annealing are often used. (1) Subcritical spheroidization below the A^sub 1^ temperature, which is mainly applied for hypoeutectoid steels. During subcritical annealing of steels with an initial pearlite structure, the cementite lamellae break up into spheroids driven by the reduction in surface energy.[3,4] (2) Intercritical spheroidization above the A^sub 1^ temperature, which is mainly applied for hypereutectoid steels in order to spheroidize and partially dissolve the grain boundary cementite. Therefore, the final microstructure of spheroidized hypereutectoid steels usually contains a bimodal distribution of cementite particles,[5,6] where large particles are located mainly on austenite grain boundaries. Numerical simulations of the intercritical spheroidization process in a high-carbon steel have shown that the rate of dissolution of the cementite lamellae also depends on the surrounding conditions.[7] This research will focus on the intercritical spheroidization annealing.

The spheroidization process of hypereutectoid steels, for instance SAE 52100 bearing steel with 1 wt pct C,[5-9] typically consists of the following three steps: (1) austenitization in the intercritical region at 1070 to 1100 K for at least 1 hour; (2) cooling from the intercritical temperature with a rate of 15 to 25 K/ h to 1020 K, and further slow cooling through the A^sub 1^ temperature to 950 K at cooling rates not faster than 5 to 10 K/h; and (3) air cooling from 1020 K to room temperature. Annealing above the A^sub 1^ temperature but below the A^sub cm^ temperature accomplishes an incomplete dissolution of cementite, then austenite with fine cementite particles normally transforms into a mixture of ferrite and cementite by either the pearlitic reaction[10] or by the divorced eutectoid transformation reaction (DET)[5,8,9,11] upon slow cooling. The latter leads to a soft microstructure of spherical cementite particles in a ferritic matrix. The main difference between these two reactions is that during the pearlitic reaction the product structure (pearlite) grows as a coupled pair of ferrite and cementite phases, whereas the DET is not a coupled reaction and requires the presence of fine but densely distributed cementite particles in the austenite. These particles grow when the austenite to ferrite transformation front passes, without nucleation of new cementite particles. In general, more carbon diffusion is required for the DET reaction. These two reactions compete during cooling from the austenitization temperature. The occurrence of either the pearlitic or the DET reaction will therefore depend strongly on the spacing between cementite particles, i.e., on the austenitization temperature and time, and on the cooling rate where slower cooung rates are favorable for the DET reaction.

Chromium (Cr) additions have a significant influence on the spheroidization of cementite. Oyama[ll] has shown that a DET- promoted spheroidized structure can be easily obtained in an ultra- high carbon steel with 1.5 wt pct Cr, but not in the equivalent Cr- free steel. In Cr-free steel pearlite formation has been observed even after low-temperature intercritical austenitization. Beswick[12] has studied the effect of Cr in bearing steels by lowering its content from 1.42 wt pct (SAE 52100 steel) to 0.03 wt pct and demonstrated that a decrease in Cr content in hypereutectoid steels influences the carbide particle size. The experiment to obtain a similar spheroidized structure with different Cr contents was not fully successful, and the finer microstructure in steels with higher Cr content was explained from the finer initial pearlite lamellae spacing. Verhoeven[5] has given an alternative explanation for the finer cementite size in high-Cr steels. The cementite particle size is controlled by the spheroidization/dissolution rate at the austenitization temperature and this rate is reduced by the addition of carbide-forming elements such as Cr and Mn. However, Mn is found to promote pearlite formation during the spheroidization process.[5] Consequently, the effect of Cr, particularly at lower Cr contents, and other alloying elements on the DET reaction is not well understood yet.

In this research, spheroidization processes are designed on the basis of thermodynamic and kinetic calculations for hypereutectoid steels with different Cr contents varying from 0.5 to 3.4 wt pct. The microstructural evolution is observed and quantified using optical microscopy. The mechanism of the DET reaction in hypereutectoid steels is discussed and the effect of Cr additions on the DET reaction is explained.

II. EXPERIMENTAL PROCEDURE

The steel compositions studied are listed in Table I. The Cr content is varied between 0.5 and 3.4 wt pct, while the concentrations of the remaining alloying elements (C, Si, and Mn) are almost the same as in SAE 52100 steel. It should be noted that the 1.5Cr steel is equivalent to the commercial SAE 52100 bearing steel. All alloys were manufactured by chill casting under inert conditions using high-purity alloying metals, resulting in ingot dimensions of 40 x 40 x 160 mm^sup 3^. After casting, a chemical analysis of each ingot was made and hot isostatic pressing (HIP) was performed at a temperature of 1420 K under a pressure of 100 MPa for 4 hours, followed by furnace cooling to 1070 K at an average rate of 12 K/min and cooling to room temperature at an average rate of 35 K/ min, in order to obtain a pore-free and homogenized structure.

Thermodynamic calculations were performed using the ThermoCalc software* (TCCR version, TCFE2 database) to develop an appropriate spheroidization process. In order to obtain the time dependence of the cementite fraction as well as the cementite particle spacing at the different austenitization temperatures, the dissolution of cementite was simulated with DICTRA**[13] (version 22, TCFE2 database for thermodynamic data and MOB2 database for mobility data).

* ThermoCalc is a trademark of ThermoCalc Software Inc., SE-113 47 Stockholm, Sweden.

** DICTRA is a trademark of ThermoCalc Software Inc., SE-113 47 Stockholm, Sweden.

The designed heat treatments were carried out in a Bahr 805 dilatometer (Bahr-Thermoanalyse GmbH, D-32609 Hullhorst, Germany) using cylindrical specimens with a diameter of 5 mm and a length of 10 mm. The microstructures were quantitatively analyzed using AnalySIS image processing software (Olympus Soft Imaging Solutions GmbH, D-48149 Munster, Germany). To obtain a good contrast for the optical analysis all specimens were pre-etched in 5 pct Nital followed by Klemm’s tint etching (50 mL of saturated aqueous sodium thiosulfate solution and 1 g of sodium disulfide); after etching cementite appears in white and ferrite in black, which enables a reliable setting for the threshold value for further quantitative analysis of size and volume fraction of cementite. The Vickers hardness of all specimens was measured using the Buehler automatic microhardness testing system OmniMent MHT 7.0 rev. 1 (Buehler GmbH, D-40599 Dusseldorf, Germany) with a load of 1 kg. The hardness presented is the average of at least five values.

III. RESULTS

A. Design of the Spheroidization Heat Treatment

In order to establish an appropriate Spheroidization heat treatment and to take the effect of Cr into account, the phase diagrams were calculated using ThermoCalc software. Figure l(a) presents the quasi-binary Fe-C phase diagrams, and Figure l(b) shows the temperature dependence of the cementite fraction for the investigated steels (Table I). Three-phase regions (ferrite, austenite, and cementite), which split A^sub 1^ into two lines, are observed in the phase diagrams for all steels. Lower and upper A^sub 1^ temperatures are presented as A^sub 1^ and A’^sub 1^, respectively, in Figure 1. Characteristic temperatures from the phase diagram are listed in Table II, and it can be seen that the addition of alloying elements changes the phase equilibria for these steels. The increase in Cr content, for instance, raises the A^sub 1^ and A’^sub 1^ temperatures, slightly widens the three-phase region, and shifts the eutectoid composition to lower carbon concentration (Figure 1, Table II). As suggested in Reference 5, the DET reaction usually occurs at slow cooling and after austenitization at lower temperatures compared with the pearlitic reaction. This research focuses on the influence of the austenitization temperature and time on the Spheroidization process, therefore the cooling rate has been kept constant. The entire proposed Spheroidization heat treatment is shown in Figure 2. At first, the heat treatment proposed for commercial SAE 52100 steel[1,5] has been used, i.e., the austenitization time t^sub 1^ is taken to be 3 hours and the austenitization temperature T^sub 1^ = A’^sub 1^ + 75 K, with a cooling rate of 15 K/h from the austenitization temperature to 10 K above A’^sub 1^, followed by cooling at 5 K/h to 955 K. As shown later, different T^sub 1^ and t^sub 1^ are used to promote the DET reaction and to improve the spheroidization heat treatment for the 0.5Cr steel.

B. Microstructural Observations and Hardness Measurement

The initial microstructures of hypereutectoid Cr-containing steels after casting and HIP consist of pearlite and proeutectoid cementite at the prior austenite grain boundaries (Figures 3(a), (c), (e), and (g)). The hardness of these microstructures is in the range of 280 to 370 HV, as shown in Figure 4. The hardness increases with increasing Cr content as a result of the smaller grain size (Figure 3). The volume fraction of proeutectoid cementite according to the phase diagram changes from 0.06 in 0.5Cr steel to 0.10 in 3.5Cr steel, whereas the total equilibrium volume fraction of cementite at room temperature in all steels is around 0.15 (Figure 1). Such a pearlitic micro structure has a poor machinability, which is considered to be a disadvantage for industrial applications. In order to overcome these problems, the spheroidization annealing as described in the previous section is performed. The austenitization temperatures are 1085, 1095, 1100, and 1110 K for the 0.5Cr, 1.5Cr, 2.5Cr, and 3.5Cr steels, respectively, Le., T^sub 1^ = A’^sub 1^ + 75 K. During the spheroidization annealing the dilatation signal has been recorded, and during cooling the austenite-ferrite transformation starting temperatures T^sub start^ are determined from the dilatometry experiments. The undercoolings DeltaT A’^sub 1^ – T^sub start^, are found to be different for different heat treatments and Cr contents, and will be discussed subsequently.

The microstructure after the spheroidization heat treatment is presented in Figures 3(b), (d), (f), and (h). The 1.5Cr, 2.5Cr, and 3.5Cr steels (Figures 3(d), (f), and (h)) demonstrate a well- spheroidized structure, while the 0.5Cr steel does not show a complete spheroidization of cementite (Figure 3(b)), and the aspect ratio of the cementite particles varies from 1.2 to 10. The microstructure of this steel consists of islands of newly formed pearlite and large spherical cementite particles. To improve the spheroidization, the heat treatment is redesigned based on the idea that the austenite at the T^sub 1^ temperature should contain a sufficiently high density of undissolved cementite particles. In the case of the 0.5Cr steel, the reason for the formation of pearlite instead of a spheroidized structure is either a too high austenitization temperature (1085 K) or an excessively long austenitization time (3 hours). This results in a greatly pronounced dissolution of cementite. At high austenitization temperature cementite can also start to coarsen by Ostwald ripening.[14] The large spacing between cementite particles subsequently promotes the formation of new colonies of pearlite during cooling.

To verify this idea, three more experiments were performed. The austenitization time was reduced from 3 hours to 10 min at 1085 K, which did not produce any significant change in the final microstructure of the 0.5Cr steel. Then the temperature dependence of the cementite fraction was considered (Figure l(b)) in order to choose a lower temperature for austenitization of the 0.5Cr steel. For successfully spheroidized alloys (1.5Cr, 2.5Cr, and 3.5Cr) the volume fraction of cementite has been found to be between 0.04 and 0.06 at the austenitization temperature, whereas in the 0.5Cr steel it is only 0.025 at 1085 K. In the 0.5Cr steel a cementite volume fraction of 0.04 is expected after austenitization at 1045 K (Figure 1(b), triangle).

The obtained microstructure shows a completely spheroidized microstructure (Figure 5(a)) with a network of grain boundary cementite (Figure 5(b)). However, the cementite network is not continuous and particles are isolated from each other. It should be noted that the austenitization at 1045 K is performed for 2 hours, and this time is apparently not long enough to sufficiently reduce the cementite network. Austenitization at 1045 K is then prolonged to 5.5 hours which, according to the calculated diffusional distances, should be long enough to completely break up the grain- boundary cementite network. However, during cooling after austenitization at 1045 K for 5.5 hours the formation of lamellar cementite is observed (Figure 5(c)), which was likely due to particle coarsening during austenitization. The spheroidized microstructure obtained after austenitization at 1045 K for 2 hours (Figures 5(a) and (b)) is considered to be optimal for 0.5Cr steel.

The measured hardness for all steels is presented in Figure 4. It should be noted that after spheroidization the hardness is found to be around 190 HV for all steels, independent of Cr content. The variation in the different measurements (the error bars) appears to be very small compared with that for pearlitic microstructures (Figure 4), which is an indication of a uniform spheroidized microstructure with the same particle size distribution. It is known[1,9] that the hardness of the material is directly related to the degree of spheroidization, size, and spatial distribution of spheroidized particles. It seems that the particle size and the size distribution play a dominant role in hardness rather than the composition.

C. Quantitative Analysis of Spheroidized Microstructures

All spheroidized microstructures are quantitatively analyzed using image analysis software. To set a reliable threshold value (Figure 3(i)) for analysis, a tint-etching technique has been used, which makes cementite appear in white and ferrite in black/brown. Typically more than 15,000 particles per alloy were analyzed, giving a sufficient statistical sampling area. The size distributions of cementite particles for the 0.5Cr, 1.5Cr, 2.5Cr, and 3.5Cr steels are shown in Figure 6. A bimodal distribution of particles is observed. The particle size distribution is normally described using a lognormal distribution function.[15] Due to the presence of two clear peaks in the probability function distribution P(d), the size distribution of the cementite particles is fitted using the summation of two lognormal distribution functions:

where f^sub i^ is the volume fraction of cementite particles, subscript i relates to the small or large particles, and f^sub S^ + f^sub L^ = 1, d is the particle diameter, the mean d^sub i^ and the standard deviation sigma^sub i^ of the distributions are given through M^sub i^ and S^sub i^, as d^sub i^ = exp (M^sub i^ + 1/ 2S^sup 2^^sub i^) and sigma^sub i^ = [the square root of]exp (2M^sub i^ + 2S^sup 2^^sub i^) – exp (2M^sub i^ + S^sup 2^^sub i^). From fitting of the experimental results with Eq. [1], where M^sub i^, S^sub i^, and f^sub i^ are fitting parameters, the volume fractions, mean particle sizes, and standard deviations of the small and large particles are obtained.

A summary of the results for the spheroidization heat treatment is presented in Table III. The degree of spheroidization, expressed as the average aspect ratio, shows that the cementite in all steels is sufficiently spheroidized. The spheroidization of high-carbon steels with different Cr contents results in a bimodal distribution of cementite particles, where almost 30 vol pct of the particles have a mean size of 0.13 mum and the rest have a mean size of 0.41 to 0.47 mum. It should be noted that the bimodal distribution arises from the particles formed at the austenite grain boundary and the particles formed within austenite grains. Verhoeven[5] made a similar observation of bimodality in the particle size distribution in hypereutectoid steels. In this research, almost the same size and size distributions of cementite particles are observed after spheroidization of steels with different Cr contents, and the hardness for all steels is approaching the optimal value for good machinability. This illustrates that by proper control of the heat treatment parameters, similar microstructures can be obtained independent of the Cr content (with an exception for the 0.5Cr steel, where the boundary cementite is spheroidized but not completely eliminated).

IV. DISCUSSION

In hypereutectoid steels, the decomposition of austenite containing cementite particles can occur either by the pearlitic reaction or by the DET reaction, depending on the austenitization process and cooling rates. Although the existence of the DET reaction has been known for years, only a limited number of studies of the mechanism and especially of the effect of alloying elements on the DET reaction are available. The work has mainly been performed on SAE 52100 bearing steel,[3-12] for which the achievement of a well-spheroidized structure is necessary before the subsequent machining and further bainitic or martensitic heat treatment.[15,16]

This work has shown that a change in Cr content in hypereutectoid steels has a significant influence on the cementite spheroidization process. The austenitization of high-Cr steels can be performed at higher temperatures without the promotion of the pearlitic reaction, which is opposite to the effect of Mn experimentally found by Verhoeven[5] and Beswick.[12] It is possibly not only due to an increase of the A’^sub 1^ temperature with Cr content, but also because Cr is a very strong carbide former leading to a sufficient amount of cementite even at austenitization temperatures as high as A’^sub 1^ + 75 K, and coarsening/dissolution of cementite is slower due to Cr additions. The advantage of using such high austenitization temperatures is the increased possibility to dissolve the grain-boundary cementite network present in the initial pearlitic microstructure. In low-Cr steel it is necessary to decrease the austenitization temperature to A’^sub 1^ + 40 K in order to promote the DET reaction, i.e., to reduce the particle spacing after the austenitization treatment. A kinetic model for the DET reaction has recently been proposed by Verhoeven.[17] This model assumes that during austenite to ferrite transformation carbon diffuses away from the moving interface, both into austenite and ferrite toward the pre-existing cementite particles. The carbon diffusion fluxes make the cementite particles grow without nucleation of new cementite particles. Verhoeven[17] has analyzed the carbon flux balance at the austenite-ferrite interface located between two cementite particles and has shown that the rate of the DET reaction can be expressed as a function of the cementite particle spacing at the austenitization temperature and the degree of undercooling at which the ferrite formation starts. It is clear that large undercoolings lead to high interface velocities and large particle spacings necessitate considerable carbon diffusion for the DET reaction, so that both (large undercoolings and large particle spacings) favor the pearlitic reaction. Verhoeven[17] has also compared the DET growth velocities for an Fe-C alloy with that of pearlite growth, and found a transition line for undercoolings and particle spacings below which the DET reaction is completed before pearlite has had time to nucleate.

In this research, the undercoolings are found from the dilatometry experiments as DeltaT = A’^sub 1^ – T^sub start^, where T^sub start^ is the austenite-ferrite transformation starting temperature. The particle spacings at the austenitization temperatures are calculated with DICTRA software, assuming that the initial particle size is about 0.4 mum. The fact that the intercritical spheroidization process was studied allows us to assume that pearlite lamellae have already been broken during heating and the dissolution of cementite particles occurs during the isothermal holding at austenitization temperatures. This assumption is supported by metallurgical observations on the samples quenched immediately after reaching the austenization temperature. For the well-spheroidized microstructures, the particle spacing at austenitization temperatures can also be estimated using results of the optical microscopy. The number of particles per unit area is the same at room and austenitization temperatures, since there is no nucleation of new particles during the DET reaction. The distances between particles at austenitization temperature are found to be close to that calculated with DICTRA, which shows that the assumption for the initial particle size is reasonably accurate.

Since the addition of alloying elements changes the phase diagram, the carbon concentrations at the interface, the rate of particle dissolution at austenitization treatment, etc., the transition line can be significantly different for different alloys. The transition line in the graph of cementite particle spacing vs undercooling is calculated using Verhoeven’s approach1171 considering the influence of Cr on the phase diagram (Figure 7(a)). Note that each line represents the transition between the pearlitic and the DET reaction for a particular alloy. The predicted transition line shifts upward with increasing Cr content (Figure 7(a)). It is shown that the austenitization temperature/time region leading to particle spacings for which the DET reaction will occur upon cooling becomes larger with an increasing amount of Cr (Figure 7(a)). Thus the difficulties in spheroidization of the low-Cr steels can now be explained. For a successful spheroidization of low-Cr steel, the austenitization time and temperature must be chosen such that the particle spacing before the cooling process is not more than 0.8 to 0.9 [mu]m (Figure 7(a)). If particle spacing is larger than 0.8 to 0.9 [mu]m, slower cooling rates than used in the present work must be considered (5 K/h). The transition lines are in agreement with the experimental results (Figure 7(a), symbols). The symbols below the transition line show the experimentally observed spheroidized structures, and symbols above the transition line demonstrate the fully pearlitic structures. Triangles (0.5Cr steel) in the vicinity of the transition line refer to microstructures that have not been completely spheroidized (Figure 3(b)) and exhibited both pearlitic and spheroidized cementite.

Using this approach, the design of the spheroidization process becomes significantly easier. By analyzing the transition lines for the different alloys, the right cementite particle spacing (the combination of the austenitization temperature and time) and the cooling rate can be chosen without performing a range of long experiments in order to successfully obtain spheroidized structures. For instance, the pearlite-promoting effect of Mn experimentally observed in the literature[5,12] can now also be predicted using the described approach (Figure 7(b)).

V. CONCLUSIONS

The effect of Cr on the spheroidization process has been studied, and the following can be concluded.

1. Spheroidized microstructures in hypereutectoid steels with different Cr contents are obtained after intercritical spheroidization heat treatment, i.e., by the promotion of the DET reaction. A bimodal distribution of spheroidized cementite particles is observed.

2. The DET reaction occurs at lower undercoolings compared with the pearlitic reaction, and the promotion of the DET reaction depends strongly on the carbide particle spacing at the austenitization treatment.

3. Chromium has a significant effect on the spheroidization process. Chromium addition increases the austenitization temperature/ time region for which the DET reaction will occur upon cooling. In low-Cr or Cr-free steels the promotion of the DET reaction becomes difficult. A proper control of the cementite particle spacing at the austenitization treatment and the cooling rate helps to overcome this problem and to obtain sufficiently spheroidized structure in low-Cr steels as well.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the industrial partners SKF and Corus Group, particularly Drs. J. Slycke, R.H. Vegter, R. Mostert, and Mr. P. Neuman for their continuous interest in this research.

OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

REFERENCES

1. K.E. Thelning: Steel and Ils Heat Treatment, Buttenvorth and Co., London, 1984, pp. 207-12.

2. W. Knorr and H. Voge: in Steel. A Handbook for Materials Research and Engineering, vol. 1, Verein Deutscher Eisenhuttenleute, ed., Dsseldorf, 1992, pp. 589-603.

3. S. Chattopadhyay and C.M. Sellars: Metallography, 1977, vol. 10, pp. 89-105.

4. D. Hernandez-Silva, R.D. Morales, and J.G. Cabanas-Moreno: ISIJ Int., 1992, vol. 32, pp. 1297-305.

5. J.D. Verhoeven: Melatt. Mater. Trans. A, 2000, vol. 31A, pp. 2431-38.

6. E.L. Brown and G. Krauss: Metatt. Trans. A, 1986, vol. 17A, pp. 31-36.

7. F.J. Vermoten, E. Javierre, C. Vuik, L. Zhao, and S. van der Zwaag: Comput. Mater. Sd., 2007, vol. 39, pp. 767-74.

8. E.B. Damm and M.J. Merwin: in Austenite Formation and Decomposition, GM. Michal and M.D. Novak, eds., TMS, Warrendale, PA, 2003, pp. 397-413.

9. W. Hewitt: Heat Treat. Met., 1982, vol. 3, pp. 56-62.

10. R.F. Mehl and W.C. Hagel: Prog. Met. Phys., 1956, vol. 6, pp. 74-134.

11. T. Oyama, O.D. Sherby, J. Wadsworth, and B. Walser: Scripta Metall., 1984, vol. 18, pp. 799-804.

12. J.M. Beswick: Metall. Trans. A, 1987, vol. ISA, pp. 1897- 1906.

13. A. Borgenstam, A. Engstrom, L. Hoglund, and J. Agren: J. Phase Equilibria, 2000, vol. 21, pp. 269-80.

14. A.M. Cree, F.G. Foulkner, and AT. Lyne: Mater, Sd. Technol., 1995, vol. 11, pp. 566-71.

15. L. Zhao, FJ. Vermolen, A. Wauthier, and J. Sietsma: Metall. Mater. Trans. A, 2006, vol. 37A, pp. 1841-50.

16. N. Luzginova, L. Zhao, and J. Sietsma: Mater. Sd. Eng. A, 2007, vol. 448, pp. 104-10.

17. J.D. Verhoeven and E.D. Gibson: Metall. Mater. Trans. A, 1998, vol. 29A, pp. 1181-89.

N.V. LUZGINOVA, Postdoctoral Researcher, and L. ZHAO, Research Fellow, are with the Netherlands Institute for Metals Research and the Department of Materials Science and Engineering, Delft University of Technology, 2628 CD Delft, The Netherlands. Contact e- mail: [email protected] J. SIETSMA, Associate Professor, is with the Department of Materials Science and Engineering, Delft University of Technology, Delft, The Netherlands.

Manuscript submitted June 20, 2007.

Article published online January 30, 2008

Copyright Minerals, Metals & Materials Society Mar 2008

(c) 2008 Metallurgical and Materials Transactions; A; Physical Metallurgy and Materials Science. Provided by ProQuest Information and Learning. All rights Reserved.

A Review of Current Tanzanian National Environmental Policy

By Maro, Paul S

Introduction The term ‘environment’ commands a very broad meaning. It refers to the physical and biological systems that provide our basic life support, and that contribute to our psychological well-being. It incorporates air, water, land, plant and animal life including human life, the social, economic, cultural, recreational and aesthetic conditions, buildings, technologies, and the direct and indirect impacts of human activities. Generally, ‘policy’ may be thought of as ‘a coherent and agreed statement of how an organisation proposes to focus on its future mission; it sets out the nature of intended actions or inaction, and sets the boundaries within which these will take place’ (Selman 2000, p. 67). Public sector policies will normally express the ways in which legal obligations are to be efficiently discharged, public monies disbursed and permissive powers optimised.

In 1997 Tanzania adopted the National Environment Policy. The objectives of this paper are to assess the rationale, objectives and coverage or content of this environmental policy; to evaluate some of the impacts of its implementation; to examine the relationship of this environmental policy to the Environmental Management Act No. 20 of 2004 (EMA); and to make recommendations on the need to review and update the environmental policy.

The rationale for the 1997 National Environmental Policy was based on a national analysis which had revealed the following environmental problems in need of urgent action:

1 Land degradation reducing the productivity of soils in many parts of the country.

2 Lack of accessible good quality water for both urban and rural inhabitants.

3 Environmental pollution in towns and the countryside affecting the health of many people and lowering the productivity of the environment.

4 Loss of wildlife habitats and biodiversity, threatening the national heritage and creating an uncertain future for the tourist industry.

5 Deterioration of aquatic systems, particularly the productivity of lake, river, coastal and marine waters, which were increasingly being threatened by pollution and poor management.

6 Deforestation, with forest and woodland heritage being reduced year by year through clearance for agriculture, wood fuel and other demands.

The main reasons for the deteriorating state of the national environment were identified as: inadequate land and water management at various management levels; inadequate financial and human resources; inequitable international terms of trade; the vulnerable nature of some local environments; the rapid growth of rural and urban population; inadequate institutional coordination; inadequate monitoring and information systems; inadequate involvement of major stakeholders (e.g. local communities, NCOs, private sector) in addressing environmental problems; and inadequate integration of conservation measures in the planning and development of programmes.

The National Environmental Policy provides the framework for making fundamental changes that are needed to bring environmental considerations into the mainstream of decision-making in Tanzania. The overall objectives are:

1 To ensure sustainability, security and the equitable use of resources for meeting the basic needs of the present and future generations without degrading the environment or risking health or safety.

2 To prevent and control degradation of land, water, vegetation and air which constitute our life support systems.

3 To conserve and enhance our natural and manmade heritage, including the biological diversity of the unique ecosystems of Tanzania.

4 To improve the condition and productivity of degraded areas, including rural and urban settlements, in order that all Tanzanians may live in safe, healthful, productive and aesthetically pleasing surroundings.

5 To raise public awareness and understanding of the essential linkages between environment and development, and to promote individual and community participation in environmental action.

6 To promote international cooperation on the environmental agenda, and expand our participation and contribution to relevant bilateral, sub-regional regional and global organisations and programmes including treaties.

It is important to recognise that the National Environmental Policy provides for cross-sectoral and sectoral policy guidelines, instruments for environmental policy, and the institutional arrangements for environmental management.

Cross-sectoral policies

Poverty

The environmental policy pursues a proactive policy objective of natural resources conservation oriented towards the reduction of the vulnerability of the poor. sectoral policies and programmes to address poverty eradication have to take due account of the need for sustainable resource exploitation.

Population

The policy objectives on population include the following: literacy programmes with emphasis on linkages with primary environmental care, primary health care, basic shelter, food security, access to secure tenure and infrastructure; the generation of socio-demographic information, and the mitigation of the direct and induced effects of demographic changes on the environment with respect to land, water and ecosystem health; and promoting the critical role of women in population and environmental issues through increased access to education, expanding primary and reproductive health care programmes.

Technology

The primary policy objective is the promotion of the use of environmentally sound technologies, that is, technologies that protect the environment, are less polluting, use resources in a sustainable manner, recycle more of their waste products, and handle residue wastes in a more acceptable manner than the technologies for which they are substitutes.

Biodiversity

Programmes for the conservation and utilisation of biological diversity are to be pursued to prevent and control the causes of significant loss of biological diversity. Strategic measures shall be put in place for the development of biotechnology to ensure a fair and equitable sharing of the results and benefits arising out of the utilisation by foreign recipients of genetic resources originating from Tanzania.

Public participation and education

Environmental education and awareness-raising programmes are to be undertaken in order to promote informed opinion. Environmental education is to be introduced into primary and secondary school curricula to inculcate values that support responsible environmental care, and discourage attitudes that are incompatible with sustainable ways of life.

Sectoral policies

The National Environmental Policy provides sectoral policy objectives for agriculture, livestock, water and sanitation, health, transport, energy, mining, human settlements, industry, tourism, wildlife, forestry, and fisheries.

Under agriculture, the main objective is to ensure food security and the eradication of rural poverty through the promotion of production systems, technologies and practices that are environmentally sound. Specific policy objectives include: the improvement of land husbandry through soil erosion control and soil fertility improvement; intensification and diversification of agricultural production; strengthening of environmentally sound land use, monitoring, registration and management of agrochemicals; improvement in water use efficiency in irrigation, including control of water logging and salination; promotion of integrated and holistic approaches through land use planning and management.

The main objective of the livestock sector is to stimulate the development of the livestock industry in the country, taking due regard of the environment, and includes the following policy objectives: the improvement and conservation of grazing lands and preservation of feed resources; restoration and protection of grazing lands, and promotion of rotational grazing; and promotion of mechanisms for resolving conflicts among different land use interests.

In the water, sewerage and sanitation sector, the policy objectives include planning and implementation of water resources and other development programmes in an integrated manner and in ways that protect water catchment areas and vegetation cover; promotion of technology for efficient and safe water use, particularly for water and waste water treatment and recycling; institution of appropriate user charges that reflect the full value of water resources; prevention, reduction and control of pollution of the marine and coastal waters.

The policy objectives under urban centres and human settlements include integrated planning and improved management of urban centres and designation of urban land uses based on environmental impact considerations; the decentralisation of urban development through the promotion of intermediate towns and trade centres; and development of gardens, parks, greenbelts and open spaces in urban centres for public use.

The main objective in the energy sector is the sound management of the impacts of energy development and use in order to minimise environmental degradation; and the policy objectives include: minimisation of wood fuel consumption through the development of alternative energy sources and wood fuel energy efficiency; and assessment and control of development and use of energy. For the mining sector the policy objectives cover: management of the overall project cycle of mining (including reclamation and restoration of land after mining) in order to minimise adverse environmental impacts; control of mining discharges to ground and water; control of air pollution from mining areas; and strict control of the use of mercury in mining activities.

The main objective in forestry is the development of sustainable regimes for soil conservation and forest protection, taking into account the close links between desertification, deforestation, fresh water availability, climate change and biological diversity. Policy objectives include: promotion and enforcement of rational exploitation of forest resources accompanied by reforestation and afforestation to meet requirements of domestic consumption and export earnings in a sustainable manner; natural forest with biological diversity value and genetic resources will be conserved; farmers, business communities, NGOs, schools and others will be motivated to embark on tree planting.

Environmental policy instruments and institutional arrangements

The National Environmental Policy provides the following environmental policy instruments: environmental impact assessment – environmental legislation, which was adopted in 2004; economic instruments, mainly market based approaches such as prices; environmental standards and indicators; the precautionary approach; and international cooperation.

The ministry responsible for environment matters is the source of overall policy guidance and advice on the development of strategic environmental vision including formulation, analysis and appraisal of broad environmental policy and goals. The Division of Environment in the Vice President’s Office is the working-level cell of the ministry and undertakes policy analysis, develops policy choices to influence decision-making, coordinates broad-based environmental programmes, plans and projects, and facilitates meaningful involvement of civil society to broaden consensus and reduce insularity.

The National Environment Management Council (NEMC) is the technical branch of the ministry and undertakes enforcement, compliance, review and monitoring of environmental impact assessment. It carries out environmental audits, research, surveys and investigations that will assist in the proper conservation and management of the environment. The EMA (2004) established the national environmental advisory committee made up of senior officials from all ministries to advise the minister of environment, and provided for the establishment of environmental sections in all ministries and environmental committees at regional, district and village levels. The environmental policy recognises the need for cooperation and coordination of sector ministries in environmental work, and also stresses the need for capacity building in the training of environmental experts, and the establishment and strengthening of institutions responsible for systematic monitoring of the state of the environment.

Impacts of the implementation of the National Environmental Policy

To evaluate the implementation of the National Environmental Policy, the following criteria which are typically used in the development of environmental policy will be applied (Envirowise, 2005):

1 A commitment to continual improvement.

2 A commitment to comply with relevant environmental legislation.

3 Education and training of employees in environmental issues and environmental effects of their action.

4 Monitoring of progress and review of environmental performance on a regular basis (annually).

5 The policy is available to all stakeholders.

Tanzania’s environmental policy complies with the first three criteria. There is very strong commitment to conservation and sustainable management of the environment by the government and the majority of Tanzanians. There is also commitment to comply with environmental legislation, especially in the 2004 EMA. Education and training of environmental experts is also a priority, and several public and private institutions are offering various environmental courses, from certificate to degree programmes.

However, the policy has not been widely distributed in the Kiswahili language, which is used by the majority of the implementers, most of whom do not speak English. Now that the EMA has established environment units in all ministries and environmental committees at the regional, district and village levels, the National Environmental Policy has to be made available to all the levels in Kiswahili so that they can play their part in its implementation. As far as criterion (4) above is concerned, there has not been systematic monitoring of progress of implementation of the policy, and no reviews of environmental performance are undertaken annually. There are no published documents/reports on monitoring and reviewing environmental performance.

In spite of the lack of regular monitoring and review of performance, the National Environmental Policy has been the basic reference document for the development of sectoral policies. Examples of such policies and strategies include the Agricultural Policy (1997), Livestock Development Policy (1997), Agricultural sector Development Strategy (2001 ), National Forestry Policy (1998), National Action Programme to Combat Desertification (1999 2005), National Energy Policy (2000), National Water Policy (2001 ), Tanzania Development Vision 2005 (2001) and the National Strategy for Growth and Reduction of Poverty.

The EMA (2004)

This act seeks to provide the legal and institutional framework for sustainable management of the environment, prevention and control of pollution, environmental quality standards, public participation, and the basis for the implementation of international environmental agreements. The Act sets out the mandates of various actors to undertake enforcement, compliance, review and monitoring of environmental impact assessment, to facilitate public participation in environmental decision-making and to exercise general supervision and coordination matters relating to the environment.

The EMA was adopted almost 10 years after the National Environmental Policy was adopted, and has provided something of an implementation framework for the policy. The National Environmental Policy was developed when Tanzania was just beginning to implement its economic transformation programme, whereas the EMA was developed and adopted at a time when the process of privatisation of economic development was already advanced, and some lessons had been learnt so it is more up to date.

Conclusions

The current National Environmental Policy has not had much impact on environmental conservation and management, as most of the problems discussed above have intensified. There is, therefore, an urgent need to review and update the policy. The review should involve national consultation and discussion, including the participation of the resource users, as well as students, institutions of higher learning, government and environmental experts and development partners. There is also the need to mount environmental campaigns and mass education to sensitise the population on how to care for and nurture the environment that supports all our lives. People should be made aware of the economic value of the goods and services they obtain from the environment, as well as the natural capacity of the environment that should not be exceeded.

The National Environmental Policy is a comprehensive attempt to guide the conservation and management of natural resources and the environment in Tanzania. The impact of its implementation has never been assessed and, until recently, there was no legal instrument to give effect to its implementation. Now there is such an environmental law, but there is also economic transformation, globalisation and climate change which need to be taken into account in the review and updating of the environmental policy.

References

Envirowise 2005 How to write an environmental policy (http;// www.envirowise.gov.uk/page) Accessed 13 April 2008

Government of Tanzania 1997 National Environmental Policy Vice President’s Office, Dar es Salaam

Government of Tanzania 2004 Environmental Management Act (No. 20) Government Printer, Dar es Salaam

Selman P 2000 Environmental planning 2nd ed Sage Publications, London

PAUL S MARO

Department of Geography, University of Dar es Salaam, PO Box 35049, Dar es Salaam, Tanzania

E-mail: [email protected]

This paper was accepted for publication in April 2008

Copyright Royal Geographical Society Jun 2008

(c) 2008 Geographical Journal, The. Provided by ProQuest Information and Learning. All rights Reserved.

Changes to ICAI Syllabus

By Byrne, David

As the Institute of Chartered Accountants in Ireland moves forward with plans to introduce its new syllabus and associated changes to the examination system, there are opportunities for suitably qualified Chartered Accountants to bring their individual expertise and knowledge to the process. David Byrne, Examinations Manager, describes what’s happening and how ICAI members can get involved. The Institute of Chartered Accountants in Ireland (ICAI) is phasing in its new syllabus over the period 2008 to 2010. New features include continuous assessment, and a strong focus on competency in both the syllabus and the examination.

The examination parts are

* CA Proficiency 1,

* CA Proficiency 2, and

* Final Admitting Examination (FAE).

The first session of the new Final Admitting Examination will be held in September 2010.

It will comprise two core integrated case studies covering the entire syllabus, and three elective papers from which candidates must choose one from

* Auditing,

* Tax, and

* Strategic Management and Business Finance.

Case Studies

The case studies will aim to reflect as much as possible real life work-based problems, with candidates required to assume different roles depending on the material in the case. Embedded in each case study will be a variety of issues which the candidates will be expected to respond to. On the basis of those responses, candidates will be judged to be ‘competent’ or otherwise.

Candidates will be expected to demonstrate competency in terms of the depth and breadth of their knowledge.

The education system is being adapted to equip students for this assessment of their competency.

Sample Papers

Three sets of sample papers will be published well in advance of the first new syllabus FAE. Drafting of both the sample and actual examination papers will be conducted using workshop methodology.

The drafting of the two core papers will be undertaken by multidisciplinary teams of authors with significant leadership from the FAE Board and support from the Executive at ICAI.

Authoring the FAE Case Studies

ICAI is looking to recruit authors to work in teams on the development of two core FAE case studies. Authoring the case studies will be a collaborative process where members of the team will bring their individual special expertise to the assignment, complementing each other in terms of their expertise and background. Each case study will be the product of the interaction of all the authors and will reflect a fusion of their different knowledge and skills. We hope that the workshop discussions will stimulate ideas and achieve extra creativity.

How To Get Involved

Paul O’Connor, a partner with PricewaterhouseCoopers and Chairman of the Education, Training and Lifelong Learning Board at ICAI, told Accountancy Ireland that the Board is currently seeking to identify suitably qualified Chartered Accountants with an interest in becoming involved in this assignment.

“From the Board’s perspective, the new FAE represents a new and better way of assessing candidates. The case studies will be much closer to the situations that candidates will face in their professional careers. It is bound to be interesting and challenging for all those involved. The participants will be part of an exciting, creative project in a key function of the Institute – the assessment of new members,” Mr O’Connor said.

Other benefits of participating include:

* A facility to keep up to date in your preferred subject areas.

* An opportunity to enhance your soft skills and to be a team player.

* An opportunity to explore the connections between the different subject specialisms within the broad discipline of Chartered Accountancy.

* Personal networking opportunities.

* CPD recognition for your participation

* Payment

To Be Considered

You don’t have to be a past exam prize winner to participate in authoring examination papers and case studies. Volunteers should be qualified Chartered Accountants with an interest in education and in giving something back to the next generation of members. As the case studies will reflect commercial situations, a detailed technical knowledge in specialist areas is not required. It is just as important to have people with a broad range of experience as well as those with specialist knowledge and experience.

Time Commitment

You can get involved with as little as a couple of days a year commitment, spread between meetings / workshops and preparatory work.

You might indicate that you are willing to have an involvement for 12 or 24 months’ duration. Within the agreed period, the Board will identify the assignments it wishes you to work on and the time commitment required for each.

Conclusion

We need new blood in the education process as we embark on a revamped FAE. This is an opportunity for you to get involved.

To find out more about authoring at FAE level, at earlier examination levels or to help out in other areas please contact [email protected].

“From the Board’s perspective, the new FAE represents a better way of assessing candidates … participants [authoring the new examination papers and case studies] will be part of an exciting, creative project in a key function of the Institute …”

Paul O’Connor, FCA, Chairman, Education & Training Board, Institute of Chartered Accountants in Ireland.

David Byrne is Examinations Manager at the ICAI. Email: [email protected]

Copyright Institute of Chartered Accountants In Ireland Apr 2008

(c) 2008 Accountancy Ireland. Provided by ProQuest Information and Learning. All rights Reserved.

Girl’s Rapist to Be Freed in 3 1/2 Years

A FORMER soldier locked up for raping one schoolgirl and sexually assaulting two others could be released in three-and-a-half years.

Sheffield Crown Court heard 59-year-old William Cargill lured the young girls to his home by offering to sell them cigarettes.

He befriended one 13-year-old girl before plying her with alcohol and taking her to the bedroom of his home in Barnsley, where he raped her.

Cargill, who served three tours of Northern Ireland during his time in the Army, also assaulted two schoolgirls, aged 13 and 15.

He denied the attacks at his home in Grays Road, Carlton, but was found guilty of rape and nine counts of indecent assault after a trial. A jury cleared him of indecent assault against a fourth youngster.

His defence said the offences happened last year when Cargill was unemployed and suffering from ill health, following the death of his wife.

Judge John Swanson said: “You were becoming increasingly sexually attracted towards girls and, on one occasion, committed the most serious offence of all.

“You supplied drink to get her drunk and were determined to take advantage of her that night and you eventually found yourself in the bedroom with this girl. This is a very serious offence.”

After hearing pleas for leniency, due to ill-health, Judge Swanson sentenced him to a total of seven years, half of which will be served in prison and the second half on licence.

Cargill has also been placed on the sex offenders’ register for his life.

After the case, Det Con Eddie Mackenzie, of South Yorkshire Police, said: “I think the result of this case is appropriate.”

(c) 2008 Yorkshire Post. Provided by ProQuest Information and Learning. All rights Reserved.

Burger’s Lake Closes As Parasite Sickens Visitors

By Jan Jarvis, Fort Worth Star-Telegram, Texas

Jul. 17–FORT WORTH — Burger’s Lake in west Fort Worth has closed while health officials investigate whether a waterborne parasite has sickened at least eight patrons at the popular swimming hole, Tarrant County Public Health announced today.

The lake has not been confirmed as the source of the cryptosporidiosis outbreak, but health officials suspect it is involved. The owner was cooperative and closed the facility Wednesday night, agency officials said.

Anyone who visited the lake after June 23 and has become ill should seek medical care, said Anita Kurian, epidemiology division manager for Tarrant County Public Health. Physicians will contact the health agency.

“Our main concern is that individuals who get sick may transmit it to others in the community,” she said. Public health officials said there have been isolated clusters of the illness in Tarrant County over the years, but nothing of this magnitude. They don’t know how many people may ultimately be infected.

The disease can spread when an infected person goes swimming for up to two weeks after symptoms have stopped, Kurian said. The parasite also can be ingested if water goes up a person’s nose, officials said.

Cryptosporidiosis, commonly known as “crypto,” can cause severe abdominal pain and diarrhea, Kurian said. It can also cause loss of appetite, nausea and vomiting. Dehydration can occur in young children, pregnant women and other vulnerable populations. Two adults have been briefly hospitalized due to the illness.

Dozens of people called the Star-Telegram after a story about the outbreak appeared on www.star-telegram.com.

Symptoms can be pretty rough, said Jennifer Seis of Arlington, who knows of at least 18 children and adults who became ill after a birthday party at the lake this month.

“Two of them have been the emergency room and everyone else is going to their doctor,” she said. “My child didn’t eat for a week and I’ve had to take off work because of this.”

Crystal Bailey of Dallas said she started feeling sick Sunday after visiting the lake over the July 4 weekend. “I have been sick, sick, sick,” said Bailey, 25. who had not visited her doctor yet. “I couldn’t even go to work.”

The parasite cryptosporidium thrives in bodies of recreational water, including fountains, oceans, lakes, ponds, spas, backyard pools and water parks, said William Blankenship, who works in environmental health at the Tarrant County Public Health.

It is found in the feces of infected people or animals and can contaminate soil, food, water or surfaces. Public drinking water has been eliminated as a cause of the illness.

The parasite is resistant to chlorine disinfection, Blankenship said. It can survive in the environment for weeks to years. Cryptosporidium is not killed by alcohol gels and hand sanitizers.

The illness came to the attention of health officials in early July after physicians started reporting the symptoms. But it’s a mystery as to how the outbreak got started, Kurian said. “Did people come to Burger’s Lake and get infected? Or did they bring it to Burger’s Lake,” she said.

The next step in the investigation is to see if more cases are identified and wait for the test results of samples that were sent to the Centers for Disease Control and Prevention. Those results should be available Saturday, Kurian said.

Practicing healthy habits is the best way to prevent the infection.

“This is a risk you face whenever you go swimming in water,” Kurian said.

It was unclear how long Burger’s Lake would be closed. A recorded telephone message said only that the spring-fed lake would “reopen upon further notice.” Health officials that visited the lake Wednesday said it appeared to be well-maintained.

Anyone who becomes ill should seek medical attention so that physicians can contact the health department. Tarrant County Public Health is distributing information about prevention measures to operators of swimming pools, day care facilities and recreational water businesses.

The investigation is being conducted by Tarrant County Public Health, the Centers for Disease Control and the Texas Department of State Health Services.

—–

To see more of the Fort Worth Star-Telegram, or to subscribe to the newspaper, go to http://www.dfw.com.

Copyright (c) 2008, Fort Worth Star-Telegram, Texas

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Kaiser Permanente Opens New Medical Offices in Diamond Bar

On Friday, July 25, Kaiser Permanente is hosting a grand opening for its new Diamond Bar Medical Offices at 1336 Bridge Gate Drive. More than 100 representatives from local businesses, including city officials from Diamond Bar will be on hand to celebrate. The event will include tours of the new facility and a ribbon cutting ceremony.

Conveniently located at Gateway Center at the 57 and 60 Freeways, the 31,050 square-foot building houses physicians and medical care providers (including those who speak Spanish and Mandarin Chinese) in Family Medicine, Pediatrics, and Ob/Gyn. Additional services include Laboratory, Radiology, and Pharmacy.

“We’re delighted to be in the Diamond Bar community, providing care to our members who reside or work here,” says John Bigley, MD, Area Medical Director, Kaiser Permanente Baldwin Park Medical Center. “Our new facility enables us to better serve our growing membership in this area by offering convenient care and service.”

The eco-friendly design and construction of the new building demonstrates Kaiser Permanente’s commitment to the environment and to the community.

The white colored roof absorbs less heat, thereby reducing the need for interior cooling. Dual pane glazing on all exterior windows contributes to energy efficiency creating less need for heating or cooling. Automated mechanical control systems change temperature throughout the day, based on occupancy. Natural light in the central lobby reduces the need for artificial light. Automatic light shut-off switches and fluorescent light fixtures decreases the energy usage throughout the building. Flooring consists of non-PVC backed carpet as well as rubber flooring that includes recycled material and requires no compounds or cleaners for daily maintenance. The products also contribute to the internal air quality as they don’t hold dust or other allergens and help prevent the growth of bacteria and mold.

“These new features not only preserve energy and other natural resources, but they also enable us to create a healthier environment for patients and staff. And by reducing our environmental impact, we are demonstrating our commitment as being a good neighbor,” adds Dr. Bigley.

Kaiser Permanente is America’s leading integrated health plan. Founded in 1945, it is a nonprofit, group practice prepayment program with Southern California headquarters in Pasadena, California. Kaiser Permanente Baldwin Park serves over 231,000 members in the San Gabriel Valley through a network of more than 3,100 employees and 460 physicians. Facilities are located in Baldwin Park, Montebello, San Dimas, and West Covina. More information about Kaiser Permanente can be found at www.kaiserpermanente.org.

Two Dead and Four Injured in Three-Car Crash

By Gerry Holt

AN elderly couple died and four people were recovering in hospital today after a three-car crash on a busy South Wales road.

A 76-year-old man and a 74-year-oldwoman from Pontypridd were pronounced dead at the scene of the smash on the A468 in Caerphilly yesterday afternoon.

The three cars – a grey Chrysler Grand Voyager, a blue Rover 416 and a blue Renault Clio – collided between a roundabout next to Caerphilly Garden Centre and St Cenydd School at about 2.15pm.

The elderly couple who died had been in the Clio. They have not yet been named but it is thought their next of kin has been informed.

Four people in the two other cars were taken to the University of Wales Hospital, Heath, Cardiff, to be treated for their injuries, which are not thought to be life-threatening.

It is thought the four remained in hospital today.

Police closed the A468 until about 8pm last night. The incident caused heavy tailbacks on the road, the main artery between Newport and Nantgarw, which passes through Caerphilly ending at the A470.

Caerphilly council leader Lindsay Whittle today spoke of his shock at the incident.

He said he had first heard about the crash when an e-mail was sent to council employees warning of traffic disruptions in the area.

“Initially my thoughts are to express deep regret and I would like to extend my sympathies to family and friends,” said the Plaid Cymru councillor. “It’s a tragic situation.”

Within two minutes of the crash an ambulance service rapid response vehicle arrived at the scene.

Two people had freed themselves from the wreckages before the emergency services arrived.

Firefighters from Caerphilly, Pontypridd and Whitchurch, Cardiff, used hydraulic cutting equipment to free a woman from her car.

The accident was attended by two senior ambulance officers and four ambulances, which took four patients to hospital.

Officers today appealed for anyone who saw what happened to contact Gwent Police on 01633 838111 or the Collision Investigation Unit on 01633 643091.

[email protected]

(c) 2008 South Wales Echo. Provided by ProQuest Information and Learning. All rights Reserved.

On the Rise: Top Gun QB Challenge Has Grown to Five State Competition

By Eric Spruill, The Edmond Sun, Okla.

Jul. 17–The Top Gun QB Challenge is back, and bigger than ever, as 22 of the state’s top signal callers come together at Edmond Memorial to see who’s Oklahoma’s best.

Top Gun QB Challenge was founded by brothers Jared and Jason Allen, and began in Arkansas, where the event just took place for the fifth time.

And since its inception, has now grown to include Oregon, New Jersey, Pennsylvania and Oklahoma. One week from now the top two individuals from each event will meet in Tulsa, to find the best of the entire program.

Jared, who just got back from Oregon, said that he believed the challenge would grow as it has.

“I would not say that I am surprised, I had high expectations. In Arkansas we had 1,000 people out to watch this year, and we’re expecting a big crowd here in Oklahoma,” Allen said. “When we did the first event in Arkansas, we knew that we had to bring it to Oklahoma, because people are just as crazy about football here. Plus, there’s not a lot for football fans to do in July, besides sit and wait.”

The two-day event, which features local products Dax Dilbeck, of Deer Creek, Cody Crabaugh, of Edmond North, and Michael Hodges, of Santa Fe, will begin on Friday at Performance Sports Center, where the players will be put through both mental and physical challenges. Dilbeck announced Wednesday that he will be accepting a scholarship offer to Oregon State.

The Friday session will begin at run from 1:30 p.m. to 3:30 p.m. and is open to the public.

Athletes will be put through a mini-combine which will include the 40-yard dash, shuttle runs, vertical leap, and a weighted throw, which tests individuals upper body strength, without having to do the bench press.

It concludes on Saturday with five events, which will take place on the Memorial practice field beginning at 7 p.m. The events will test the players speed, mobility, accuracy and arm strength.

The Top Gun QB Challenge crew evaluates talent throughout the football season to figure out who to invite the next season, though that will change in the ’09 format.

“We send out nomination forms to coaches, and we evaluate lots of film. We talk to college coaches and the media, to get a better idea of who we should invite,” Allen said. “We’re changing that up a little bit in ’09. Next year we’re going to hold 15-20 one-day events, where any quarterback in the state can come out and compete, because we know that sometimes a player may slip through the cracks. Then we will have the best from those events compete against the guys that we feel have earned the right to be there.”

—–

To see more of The Edmond Sun or to subscribe to the newspaper, go to http://www.edmondsun.com/.

Copyright (c) 2008, The Edmond Sun, Okla.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Jury Rules Former Doctor Won’t Have to Pay Additional Damages, Attorneys’ Fees

By Natalie Singer, Seattle Times

Jul. 17–A King County jury has found that former pediatrician Bill Schnall did not communicate with minors for immoral purposes.

Today’s verdict means the jury will not award additional damages, or attorneys’ fees and costs in a civil lawsuit against Schall brought by four patients. Plaintiffs’ attorneys said their fees and costs totaled nearly $2 million.

On Wednesday, the same jury ordered the former Shoreline pediatrician to pay about $630,000 to three of the four former patients and their families who sued the physician over allegations that his treatment involved years of abuse.

The jury found that Schnall, formerly a well-respected pediatrician and onetime president of the medical staff at Children’s Hospital & Regional Medical Center, violated the standard of care for a health-care provider and that he negligently inflicted emotional distress on three of the four former patients who sued him in civil court.

The largest single award for $300,000 went to one former patient who was described as the most fragile victim and had learning disabilities. The other boys and parents received varying amounts of economic and noneconomic damages.

The jury, however, found that the clinic where Schnall worked, Richmond Pediatric Clinic, did not violate its duty to protect the boys but did negligently supervise Schnall. The jury did not order the clinic to pay damages.

The plaintiffs’ attorneys had asked for more than $20 million in combined damages for the former patients and their parents.

“We’re gratified that they found liability,” said Anne Bremner, one of the plaintiffs’ attorneys. “But the damages could have been much higher. They didn’t deserve this, especially from a pediatrician.”

Attorneys for Schnall and the clinic declined to comment until jurors returned with a verdict from the second phase of the case. Jurors are expected to return to court this morning and continue deliberating over whether Schnall communicated with minors for an immoral purpose. If they find that he did, they could award attorneys’ fees and costs, which plaintiffs’ attorneys say amount to $1.8 million.

The plaintiffs, now young adults, accused Schnall of abusing them sexually and emotionally while they were in their teens.

According to the complaint and courtroom testimony during the five-week civil trial, Schnall inappropriately touched the genitals of the plaintiffs during exams and took nude photos of one. They also claimed he secretly provided some with money, engaged them in sexually explicit discussions, sent them sexually explicit e-mails, required them to take “oaths” regarding their sexual behavior and discussed his sexual arousal with them.

Schnall would meet frequently with the boys for treatment for problems, some emotional, and had gained the support of the boys’ parents — many of whom he had known since the boys’ births.

“If he had his way, he could control their every thought … what they thought about in terms of their love lives and fantasies,” Bremner said during closing arguments. “They had to tell him everything. He had to be in their brains. These were patients from birth, and they were slowly groomed.”

The relationships began when the boys were 12 or 13 and in most cases lasted four or more years, according to the plaintiffs’ lawyers.

Schnall vehemently denied the accusations of impropriety. During closing arguments last week, his attorneys said that proper medical procedures were blown out of proportion by the boys and that the youths’ existing emotional problems were to blame for much of their suffering.

Defense attorneys argued that the boys’ stories changed over time and that the behavioral “agreements” Schnall fashioned were based in the boys’ own goals.

As part of the verdict, the jury did find contributory negligence on the part of two of the boys and some of their parents, which will reduce the damages awarded to them by 15 to 25 percent.

Schnall surrendered his medical license in May 2006, just before the state’s Medical Quality Assurance Commission was to begin hearings over the allegations against him by former patients.

After an investigation by the King County Sheriff’s Office, then-Prosecuting Attorney Norm Maleng determined there wasn’t a criminal charge his office could pursue. The doctor did, however, cross medical and professional boundaries with his actions, Maleng’s office stated at the time.

Schnall, who practiced medicine for nearly 30 years, served as president of the medical staff at Children’s Hospital in 2002 and served on the Shoreline School Board from 1989 to 1996.

Plaintiffs and their attorneys have complained that Schnall is still employed at the clinic as an office manager with access to patients’ records and information.

Natalie Singer: 206-464-2704 or [email protected]

Information from Seattle Times archives is included in this report.

—–

To see more of The Seattle Times, or to subscribe to the newspaper, go to http://www.seattletimes.com.

Copyright (c) 2008, Seattle Times

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Olmsted Medical Center Steps into the Spotlight

By Jeff Hansel, Post-Bulletin, Rochester, Minn.

Jul. 17–Olmsted Medical Center officials have taken a leap forward while looking back at the past.

The organization held a 60th birthday party Tuesday, replete with birthday cake and a room filled with Rochester Area Chamber of Commerce members.

The public event included the unveiling of a new logo and organizational motto that says “good health starts with great care.” The event included a new push to swing the spotlight squarely onto OMC.

“The Olmsted Medical Center, and its predecessors, has always kept a low profile,” said OMC’s president, Dr. Roy Yawn. “In fact, it’s been so low that people can live here for years and never know what it is… It’s time to raise that profile a bit.”

With the unveiling of its new logo and motto, the medical center has begun a very public effort to raise its image.

“Our long-term strategy is growth. That means patient services, adding doctors,” Yawn said. The organization has plans over the next few years to increase services and to expand facilities, but Yawn declined to describe specifics of projects still in the planning stages.

Plans so far call for growth in three areas:

–Patient volume

–Community awareness

–Philanthropy

This year begins the clinic’s 60th year of operation, and community members can expect the same care, but new services.

Already, Olmsted Medical Center has opened two FastCare Clinics in Rochester’s Shopko stores, spawning a spate of convenience retail clinics that now include Target Clinic and Mayo Express Care.

“We are going to rely on philanthropy to a greater extent probably than we ever have been before,” Yawn said. Several future projects will be supported by philanthropy, including facility expansion and increased services.

“We have ideas. We have some plans. But these are not specific enough to be taken public right now,” Yawn said.

—–

To see more of the Post-Bulletin, or to subscribe to the newspaper, go to http://www.postbulletin.com.

Copyright (c) 2008, Post-Bulletin, Rochester, Minn.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Ozaukee Could Build Assisted-Living Center

By DAN BENSON

Port Washington — In an ongoing attempt to financially support the Ozaukee County-owned Lasata Care Center nursing home, county officials have introduced a $12.74 million proposal to build an assisted-living facility and remodel the existing care center on the Lasata campus in Cedarburg.

In a presentation to the County Board on Wednesday, consultants and members of the county Aging and Long Term Care Committee explained that a new 60-unit assisted-living home would generate enough revenue to help the county nursing home continue operating.

Along with the care center and Lasata Heights, the county’s 60- unit independent-living facility, the assisted-living center would provide a “continuum of care” for low- to moderate-income residents not currently served by the private sector, Supervisor Kathy Geracie and others said.

Geracie is chairwoman of the Aging and Long Term Care Committee.

Under the plan, the assisted-living center, which would be built behind and to the west of Lasata Heights, would cost about $10.19 million.

Another $2.55 million would be spent remodeling the care center and reducing the number of beds there from 201 to about 160.

The proposal suggests the project be paid for through a 20-year bond issue.

The Lasata campus is on Wauwatosa Road just south of Bridge Road.

Lasata Care Center Administrator Ralph Luedtke told supervisors that it costs the county about $50 a day for each Lasata patient covered under Medicaid because state and federal reimbursements don’t match the increased costs.

Some supervisors suggested that the county would be competing with the private sector if it built an assisted-living facility.

Geracie, however, said studies show that the income range targeted by the proposed county facility is neglected by the marketplace and the county would be able to serve more senior citizens under the proposal.

“The whole reason for doing this is to meet a need that’s not being filled,” she said.

Supervisors did not vote on the proposal Wednesday.

Copyright 2008, Journal Sentinel Inc. All rights reserved. (Note: This notice does not apply to those news items already copyrighted and received through wire services or other media.)

(c) 2008 Milwaukee Journal Sentinel. Provided by ProQuest Information and Learning. All rights Reserved.

BSD Medical Responds to FDA On Its BSD-2000 PMA Application

SALT LAKE CITY, July 17, 2008 (PRIME NEWSWIRE) — BSD Medical Corporation (Nasdaq:BSDM) today announced that a formal response has been hand delivered to the Food and Drug Administration (FDA) pertaining to the BSD-2000 Hyperthermia System submission that is currently in review by the FDA. The response followed an in-person meeting with the FDA management and reviewers in which the company’s response strategy was discussed before the company made its formal response.

On January 7, 2008, the company announced that it had received a letter from the FDA regarding its Premarket (PMA) submission for the BSD-2000 Hyperthermia System providing guidance as to amendments needed to make the PMA approvable. Following receipt of this letter, BSD Medical provided a submission to FDA that discussed the guidance in the FDA letter. This FDA submission also included a request for supervisory review by the FDA and a request for a meeting with FDA to clarify certain aspects of the agency’s guidance. The meeting request was followed by an in-person meeting with the FDA management and reviewers to discuss the company’s response strategy before the company made its formal response. During this meeting and subsequent follow-up discussions, FDA has signaled a willingness to work interactively with the BSD Medical on this submission. Following this meeting, study data on approximately 400 additional patients treated with the BSD-2000 became available to the company, and BSD has subsequently obtained additional details regarding the new study data. Using these additional data, in conjunction with data previously available, the company has submitted a formal response to the FDA on the BSD-2000 Hyperthermia System PMA application that incorporates the guidance provided by FDA.

BSD Medical has received FDA Pre-Market (PMA) approval for the BSD-500 Hyperthermia System and administered the PMA approval process for the TherMatrx TMX-2000 used to treat benign prostatic hyperplasia. BSD currently has two FDA submissions in progress, a Pre-Market (PMA) submission for the BSD-2000 Hyperthermia System and a 510(k) premarket notification seeking FDA marketing clearance for the MicroThermX-100 Ablation System.

About BSD Medical Corporation

BSD Medical Corporation is the leading developer of systems used to deliver hyperthermia therapy for the treatment of cancer. Hyperthermia therapy is used to kill cancer directly and increase the effectiveness of companion radiation treatments for certain tumors. For further information visit BSD Medical’s website at www.BSDMedical.com or BSD’s patient website at www.treatwithheat.com.

Statements contained in this press release regarding the Company’s Pre-Market submission for the BSD-2000 Hyperthermia System and the 510(k) submission for FDA clearance of the MicroThermX 100 Ablation System that are not historical facts are forward-looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to risks and uncertainties. We wish to advise readers that a number of important factors could cause actual results to differ materially from historical results or those anticipated in such forward-looking statements. These factors include, but are not limited to, those risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Form 10-K for the fiscal year ended August 31, 2007, and other filings with the SEC. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

This news release was distributed by PrimeNewswire, www.primenewswire.com

 CONTACT:  BSD Medical Corporation           Hyrum A. Mead           (801) 972-5555           Fax: (801) 972-5930           [email protected] 

ABELSoft Corporation’s ABELMed PM – EMR V 8 Receives 2007 Conditional CCHIT Certification

NIAGARA FALLS, N.Y., July 17, 2008 (PRIME NEWSWIRE) — ABELSoft Corporation, a market leader in providing healthcare IT solutions for over 30 years, today announced that their product ABELMed PM – EMR v 8 has successfully achieved pre-market, conditional certification by the Certification Commission for Healthcare Information Technology (CCHIT(r)), and meets the Commission’s ambulatory electronic health record (EHR) criteria for 2007. Pre-market, conditionally certified EHRs are new products that comply with 100 percent of updated 2007 Certification Criteria and are fully certified once their operational use at a physician office site has been verified. Ambulatory EHRs are designed for physician offices and clinics where most Americans get their healthcare. CCHIT — an independent, nonprofit organization — is the Recognized Certification Body in the United States for certifying health information technology products.

“ABELSoft Corporation is proud to be a market leader in providing practice enhancing healthcare IT solutions”, said Arun Rele, President and CEO of ABELSoft. “Our Microsoft Gold Certified Partner status, achieved by less than 1% of the partners, positions us to leverage the latest available technologies to develop the best possible solutions for healthcare professionals. ABELSoft is committed to delivering certified solutions that make it easy for physicians and other healthcare providers to implement interoperable Electronic Health Records which incorporate widely accepted industry standards, a goal shared by the Certification Commission. We think that such standards are vital to the industry and we share the Commission’s dedication to continually raising the bar to assist the end user in making the right choices for EHRs.”

Mr. Rele also stated that, “We believe our recertification for 2007 confirms our ongoing commitment to provide healthcare professionals with flexible, scalable, clinically utile and fully integrated EMR solutions. Our developers are already working towards meeting and exceeding the 08 certification criteria and we are confident we will achieve it very soon. Our time-tested and perfected scheduler, multiple options for entering data, customizable templates, e-Prescribing, automatic drug interaction checks, document management, and a comprehensive billing module are just a few examples of how ABELMed PM – EMR can streamline ambulatory practices. I urge physicians and other healthcare professionals to discover these features and take advantage of our incentives program.”

In the second year of the program’s operation, the criteria and testing have been significantly enhanced. The Commission added 96 criteria to the 151 original requirements from last year. As a CCHIT Certified product, ABELMed PM – EMR has been tested and passed inspection of 100 percent of a set of updated criteria for functionality, interoperability and security.

“For 2007, the Commission raised the bar from the previous year’s criteria. Ambulatory EHRs now must include electronic prescribing, demonstrate an ability to receive lab results, and show enhanced patient safety, quality, and security features,” said Mark Leavitt, M.D., Ph.D., chair, CCHIT. “Investment in 2007 certified ambulatory EHRs gives providers even more powerful tools to improve quality, safety and efficiency while protecting the privacy of health information.”

The CCHIT Certified mark — a “seal of approval” for EHR products — provides the first consensus-based, government-recognized benchmark for ambulatory EHR products. By looking to products with the CCHIT Certified seal, physicians and other providers can reduce their risk in selecting an EHR product, allowing them to focus their evaluation on the special needs of their practices.

CCHIT’s certification compliance criteria and its design for a certification inspection process have been thoroughly researched, taking into account the state of the art of EHRs and available standards, and comparing certification processes in other industries and other countries. The inspection process is based on real-life medical scenarios designed to test products rigorously against the clinical needs of providers and the quality and safety needs of healthcare consumers and payers. One script, for example, recreates a scenario of an elderly man with poorly controlled diabetes, hypertension and other chronic conditions in order to test EHR functions such as potential adverse drug reactions, disease management and treatment plans.

About ABELSoft Corporation

ABELSoft Corporation develops ABELMed and ABELDent clinical and practice management software and serves 10,000 healthcare professionals across North America. Specialists in developing healthcare software since 1977, ABELSoft uses the latest Microsoft technologies, provides unparalleled customer service and telephone support 24/7/365, with calls answered live during our business hours. More information on ABELSoft’s products and services is available at www.abelsoft.com.

The ABELSoft Corporation logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4966

About CCHIT

The Certification Commission for Healthcare Information Technology (CCHIT(r)) is an independent, nonprofit organization that has been named by the federal government as the Recognized Certification Body for health information technology. Its mission is to accelerate the adoption of health information technology by creating a credible, sustainable certification program. The certification requirements are based on widely accepted industry standards and involve the work of hundreds of expert volunteers and input from a variety of stakeholders throughout the health care industry. More information on CCHIT and CCHIT Certified(r) products is available at www.cchit.org.

“CCHIT(r)” and “CCHIT Certified(r)” are service marks of the Certification Commission for Healthcare Information Technology.

This news release was distributed by PrimeNewswire, www.primenewswire.com

 CONTACT:  ABELSoft Corporation           Media Contacts:            Gayle Milson            800-267-ABEL (2235)            [email protected]            CCHIT           Sue Reber             503...             [email protected]            ABELSoft Corporation           Sales Contact:           Bina Rele, VP Sales           800-267-ABEL (2235)           www.ABELSoft.com           www.ABELMed.com 

Inquiries Urged in Dental Deaths: Settlement Reached in One Case

By Karen Dorn Steele, The Spokesman-Review, Spokane, Wash.

Jul. 17–The head of the Washington state Department of Health, responding to newspaper reports this week, is calling for all patient deaths linked to dental surgery to be investigated.

Mary C. Selecky’s letter to the head of the Dental Quality Assurance Commission came after recent investigations by the Seattle Post-Intelligencer and The Spokesman-Review into the commission’s decision not to investigate three recent patient deaths.

“We are taking this issue very seriously,” said Health Department spokesman Donn Moyer.

James “Jimmy” Marks, a Spokane Gypsy leader, died last year in a Spokane hospital after dental surgery in the office of Spokane dentist Mark C. Paxton. A Seattle man died after his wisdom teeth were removed, and an elderly woman died after Spokane oral surgeon Dr. Terrance Hauck removed her teeth in 2005 in preparation for dentures. The Spokesman-Review found a fourth, unreported case of a Spokane man who died following palate surgery.

“A patient death is a very serious matter. While these deaths are rare, I’m sure you agree that they must be taken very seriously,” Selecky said in her letter to Spokane dentist Pramod Sinha, chairman of the Dental Quality Assurance Commission.

“If every case is investigated, the commission can be assured it has all the details needed to make an informed decision for patient safety and public protection,” Selecky said in her letter.

The dental commission didn’t have an immediate response to the letter.

The Health Department has also revised its Web site this week — cross-referencing every license held by a provider — so that consumers can more easily access information about any action taken against a health provider. That was an issue in the Hauck case, where the death of the 89-year-old woman was noted under his medical license but not under his dental license because the dental commission took no disciplinary action.

The Department of Health’s Medical Quality Assurance Commission also announced a settlement in the Hauck case, which was being negotiated last week before the newspaper articles were published. Hauck will pay a $10,000 fine, and his medical license will be placed on probation for two years, state records show.

Hauck must also use a certified anesthesia provider for high-risk patients and must take an annual class in sedation procedures. State investigators will review his records every six months during his probation.

—–

To see more of The Spokesman-Review, or to subscribe to the newspaper, go to http://www.spokesmanreview.com.

Copyright (c) 2008, The Spokesman-Review, Spokane, Wash.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Weight No More! The BET Foundation’s Summer Camp for Girls is Back for Its 4th Year!

WASHINGTON, July 17 /PRNewswire/ — With obesity in young children rising at alarming rates in our nation, the BET Foundation is back with its acclaimed “Summer Camp For Girls” running from July 20-27, 2008. Sponsored by BET Networks, General Mills, SUBWAY(R) Restaurants, and Wal-Mart Stores, the BET Foundation’s “Summer Camp For Girls” will take place at the Alabama 4-H Youth Development Center campsite located in Columbiana, AL. This year’s program supporters include the University of Alabama-Birmingham, School of Social Work, African-American Health Coalition of Houston, TX, Nek Nak, Charles the Chef, and the Alabama Cooperative Extension System.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070716/BETNETWORKSLOGO )

The week-long camp was specifically designed as an effective approach to help African-American girls and their parents identify and practice lifestyle changes that will assist in achieving and maintaining a healthy body weight and a positive self-image through health literacy, physical activity, healthy lifestyle choices, proper nutrition, and self-appreciation. The program components include: daily exercise & fitness activities; nutrition classes, healthy cooking demonstrations for kids, Media Smart Youth; art therapy; group counseling and self-esteem workshops; trust and confidence building exercises; arts and crafts; talent and fashion shows; movie nights; and special celebrity guest appearances. This year, Toccara Jones, Keri Hilson, Tiffany Evans, Teyanna Taylor and Miss Black USA, Kristen White will be on hand to share their experiences and encourage the young ladies to meet their goals of achieving a healthy lifestyle. The camp will also feature special guest nutritionist, Shirley Dolland from the Bell Institute for Health and Nutrition, an extension of General Mills.

The BET Foundation created this special camp as an innovative weight reduction and nutrition-based program for African-American girls ages 10 – 12 from low to moderate-income families. “The purpose is to provide young girls with the vital information and tools necessary to aid them in making healthy lifestyle choices, and to serve as a “health” advocate for their family and peers,” states Lynda Dorman, Executive Director and Vice President. The camp curriculum will provide simple nutrition strategies; instill positive leadership and decision-making skills; and provide a fun-filled, memorable camp experience.

“General Mills is proud to extend its partnership with the BET Foundation’s Summer Camp For Girls. The camp aligns with our corporate mission to ‘Nourish Lives’ and encourage consumers to lead healthier lives by

making small changes that yield big results,” states Kimberley Bow Sunday, Multicultural Marketing Manager.

One hundred and fifty young girls from various states including Wisconsin, Maryland, Virginia, Florida, New York, Tennessee, Alabama, North Carolina, Georgia, South Carolina, Illinois and Pennsylvania were selected for this wonderful, free of charge camp experience based on essays their parent/guardians submit expressing why they should participate in the one-week fitness program and how the experience will influence a healthier lifestyle. This summer, 120 girls were chosen.

“SUBWAY(R) Restaurants are very excited to be partnering with the BET Summer Camp for Girls,” said Shannon Bowers, Brand Manager for the Subway Franchisee Advertising Fund Trust. “Grass roots initiatives such as this truly give the Subway brand a platform to support the African-American community as more people are choosing healthy, active lifestyles.”

ABOUT BET

BET Networks, a subsidiary of Viacom, Inc. , is the leading provider of media and entertainment for African Americans and consumers of Black culture on a global basis. The primary BET cable network reaches more than 84 million households and can be seen in the United States, Canada and the Caribbean. BET Digital Networks – BET J, BET Gospel, and BET Hip-Hop — are brands that combine to serve a broader and more diverse audience than the core network. BET.com is the number one internet destination for the target audiences. BET Mobile delivers music, gaming, and video content to the target audiences on wireless devices across virtually all service providers. BET Event Productions is a full-scale event management and production company with festivals and live events spanning the globe. BET International delivers BET content to the consumers of Black culture around the world. BET Networks inspires its audiences to make a difference in their lives and communities with a series of impactful pro- social initiatives under the Touch BET umbrella.

ABOUT BET FOUNDATION

The BET Foundation is a 501(c)(3) non-profit organization created to raise public awareness to the numerous health-related challenges within African- American communities. Established in 2003, the BET Foundation takes a pioneering step in addressing the prevalence of obesity and related health concerns among African-Americans. Through specifically-tailored initiatives and targeted campaigns, the BET Foundation aims to insure that African Americans live longer and healthier lives. The BET Foundation includes public service announcements (PSAs); targeted programming segments; women’s health symposiums and forums; health brochure materials; a dedicated toll-free hotline and website; and a nationwide Healthy BET Fitness Challenge contest to provide the tools and knowledge necessary for communities to develop long lasting healthy lifestyle habits. For more information, please visit http://www.ahealthybet.com/.

ABOUT GENERAL MILLS

General Mills(R), with annual net sales of $13.4 billion, is a leading global manufacturer and marketer of consumer foods products based in Minneapolis. General Mills’ mission is Nourishing Lives – innovating to make lives healthier, easier, and richer – while Nourishing Communities and Nourishing the Future. Its global brand portfolio includes Cheerios, Betty Crocker, Pillsbury, Green Giant, Haagen-Dazs, Nature Valley, Old El Paso and more. With more than 100 consumer brands and operations in more than 100 countries, General Mills is also a leading supplier of baking and other food products to the foodservice and commercial baking industries.

Photo: http://www.newscom.com/cgi-bin/prnh/20070716/BETNETWORKSLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

BET Networks

CONTACT: Sonya Lockett of BET Networks Public Affairs, +1-212-205-3012,[email protected]; or Bernadette Simpao of BET Networks CorporateCommunications, +1-212-205-3145, [email protected]

Web site: http://www.bet.com/http://www.ahealthybet.com/

Moses Taylor Hospital Selects PCTS’ Amelior EDTracker Software

Patient Care Technology Systems, a subsidiary of Consulier Engineering, has announced that Moses Taylor Hospital has selected the company’s Amelior EDTracker software to automatically track patients and assets in its 35,000 census emergency department.

The software will use ultrasound locating from Patient Care Technology Systems (PCTS) partner Sonitor technologies.

The company said the Amelior EDTracker utilizes real-time location technologies to automatically capture real-time location information. Wireless patient, staff and asset tags communicate their real-time location to a network of sensors positioned throughout the department.

The PCTS automatic tracking software receives this information and applies ED-specific workflow rules which measure location, movement and interactions between patients, staff and clinical equipment in order to identify and communicate patient care milestones as they occur. Caregivers utilize configurable map and status view screens within Amelior EDTracker to anticipate and manage their workflow.

All patient movement is automatically measured and time-stamped which is accessible through the software’s extensive workflow reporting tools. An integrated dashboard informs department leadership about surges in patient volume by communicating key patient flow metrics in real-time.

The Sonitor ultrasound indoor positioning system will provide automatic capture of real-time location data. The ultrasound tags utilize sound waves to communicate to detectors throughout the department. The sound-based locating technology creates no electromagnetic interference with medical devices.

Brigham and Women’s Hospital Signs With LodgeNet Healthcare to Provide Patient Education and on Demand Entertainment Solutions

BOSTON and SIOUX FALLS, S.D., July 17 /PRNewswire-FirstCall/ — Brigham and Women’s Hospital and LodgeNet Healthcare, a division of LodgeNet Interactive Corporation , announced an agreement that brings the LodgeNetRX(TM) Interactive Patient Television System to more than 700 patient beds at Brigham and Women’s Hospital in Boston. Brigham and Women’s Hospital, an internationally renowned teaching affiliate of Harvard Medical School, launched the system this July to provide patients with access to on demand entertainment and patient specific education.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080115/AQTU120LOGO)

In support of this agreement, LodgeNet completely re-designed the hospital’s patient TV network and installed the company’s video on demand (VOD) movies, music, and its patient education management solution (which, when fully implemented, will be provided in conjunction with Patient Edu, LLC).

“We did a thorough evaluation of interactive system options in the market and selected the most reliable, proven and scalable system to support our goals of better educating and empowering patients,” said Jennifer Nadelson, MBA, administrative director, Brigham and Women’s Hospital. “LodgeNet’s track record and expertise in planning, managing, and implementing their solutions assured us that the project would be handled professionally and efficiently.”

“The LodgeNet installation crew was professional and handled our cable plant and infrastructure project seamlessly,” added Nadelson. “We look forward to enhancing our patient experiences in the future with the features of this new system.”

A growing number of hospitals now offer hotel-like amenities to ease the stress of hospital stays, and a recent survey conducted by LodgeNet showed that hospitals with interactive patient television systems enjoyed greater patient satisfaction ratings and other benefits than hospitals without such systems. The research supported a key theme that is well recognized by hospital employees: when patients have easy access to rich interactive media, entertainment content and medical information, they feel more empowered and satisfied with their experiences. In addition, U.S. hospitals see some five million re-admissions a year, and experts cite better patient education as one potential opportunity to reduce this number.

Ann Furey, RN, Patient Education Program manager, said, “LodgeNet Healthcare and Patient Edu, LLC are working with my team to better understand our Patient Education Program principles. Brigham and Women’s Hospital strives for excellence in all aspects of patient care, and patient education is no exception. We intend to advance our efforts toward this goal through the application of this solution in our patient interactions.”

“To have such a prestigious hospital rely on LodgeNet for their patient education and entertainment needs speaks volumes about the service they know we can deliver,” said Gary Kolbeck, vice president of Healthcare Business Development for LodgeNet. “Our system can benefit not only the patient but the hospital as well with improved operational efficiencies.”

Brigham and Women’s Hospital is consistently ranked among the top American hospitals and has been ranked on US News and World Report’s Honor Roll of America’s best hospitals for 11 consecutive years. It is the only hospital in the nation to be named for eight consecutive years to Solucient’s list of Top 100 Hospitals. In 2008, it was recognized by the University HealthSystem Consortium (UHC) for being one of five top performing academic medical centers in the country in a quality and safety benchmarking study.

The LodgeNetRX Interactive Patient Television System is a leading solution supporting a growing trend in which more hospitals and healthcare facilities are seeking to deploy interactive TV systems as a way of better informing and empowering patients throughout the continuum of care. LodgeNet Healthcare has sold its interactive systems to 31 healthcare facilities to date. The company will be demonstrating its LodgeNetRX solution at the 45th Annual Conference & Technical Exhibition of the American Society for Healthcare Engineering (ASHE) of the American Hospital Association (AHA), July 20-23 in Washington, DC. For more information, please visit the LodgeNet Healthcare Website at http://www.lodgenetrx.com/.

About Brigham and Women’s Hospital

Brigham and Women’s Hospital (BWH) is a 757-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. In July of 2008, the hospital opened the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 860 physician-investigators and renowned biomedical scientists and faculty supported by more than $416 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses’ and Physicians’ Health Studies and the Women’s Health Initiative. For more information about BWH, please visit http://www.brighamandwomens.org/.

About LodgeNet Interactive

LodgeNet Interactive Corporation is the leading provider of media and connectivity solutions designed to meet the unique needs of hospitality, healthcare and other guest-based businesses. LodgeNet Interactive serves more than 1.9 million hotel rooms representing 10,000 hotel properties worldwide in addition to healthcare facilities throughout the United States. The company’s services include: Interactive Television Solutions, Broadband Internet Solutions, Content Solutions, Professional Solutions and Advertising Media Solutions. LodgeNet Interactive Corporation owns and operates businesses under the industry leading brands: LodgeNet, LodgeNetRX, and The Hotel Networks. LodgeNet Interactive is listed on NASDAQ and trades under the symbol LNET. For more information, please visit http://www.lodgenet.com/.

LodgeNet and LodgeNetRX are trademarks or registered trademarks of LodgeNet Interactive Corporation. Other trademarks are the property of their respective owners.

Photo: http://www.newscom.com/cgi-bin/prnh/20080115/AQTU120LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

LodgeNet Interactive Corporation

CONTACT: Ann Parker, Director of Corporate Communications of LodgeNetInteractive Corporation, +1-605-988-1000, [email protected]; orinvestors, Mike Smargiassi, [email protected], or media, Ray Yeung,[email protected], both of Brainerd Communicators, +1-212-986-6667, forLodgeNet Interactive Corporation

Web site: http://www.lodgenet.com/

NASONEX(R) Now Approved in Japan for the Treatment of Allergic Rhinitis in Adult Patients

KENILWORTH, N.J., July 17 /PRNewswire-FirstCall/ — Schering-Plough Corporation today announced that Schering-Plough K.K., the company’s country operation in Japan, has received marketing approval for NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg* for the treatment of allergic rhinitis in adult patients.(1) NASONEX is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. NASONEX is the first intranasal steroid to be approved in Japan for once-daily administration. NASONEX is currently approved in over 100 countries worldwide and is anticipated to be available in Japan this fall.

“Allergies are a growing health problem in Japan,” said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. “NASONEX provides physicians with an important treatment option for the relief of nasal allergy symptoms, especially for those patients looking for the convenience of a once-daily treatment.”

Allergic rhinitis, which encompasses the outdoor symptoms of seasonal allergic rhinitis (SAR) and the indoor symptoms of perennial allergic rhinitis (PAR), affects an estimated 18 to 23 million people in Japan. Nasal allergy symptoms classically include sneezing, nasal itching, nasal discharge and congestion. Japan is the world’s second largest market for prescription and over-the-counter medications for the treatment of allergies.

About NASONEX

In the United States, NASONEX is indicated to treat nasal symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older, as well as nasal polyps in adults 18 years of age and older.(2) NASONEX is also proven to help prevent most seasonal nasal allergy symptoms in adults and children 12 years of age and older when NASONEX is started 2 to 4 weeks prior to allergy season.(2) NASONEX is nonsedating and not addictive when used as directed.(1) Side effects were generally mild and included headache, viral infection, sore throat, nosebleeds and coughing.(2) Full Prescribing Information is available at http://www.spfiles.com/pinasonex.pdf .

About Schering-Plough Corporation

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com/.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential market for NASONEX. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough’s forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part I, Item IA. “Risk Factors” in Schering-Plough’s 2008 Q1 10-Q.

   * calculated on the anhydrous basis    References:    1. NASONEX(R) Package Insert. Schering-Plough K.K.    2. NASONEX(R) (summary of product characteristics). Schering Corporation.  

Schering-Plough Corporation

CONTACT: Media, Julie Lux, +1-908-298-4774, or Gail Thornton,+1-908-298-5313, or Investors, Janet Barth or Joe Romanelli, +1-908-298-7436,all of Schering-Plough Corporation

Web site: http://www.schering-plough.com/http://www.spfiles.com/pinasonex.pdf

Company News On-Call: http://www.prnewswire.com/comp/777050.html

MedX(R) Announces Agreement With Technology4Medicine To Expand Product Distribution in the U.S. Market

MISSISSAUGA, ON, July 17 /PRNewswire-FirstCall/ — MedX Health Corp. (TSXV: MDX) today announced an exclusive distribution agreement with Technology4Medicine, a newly formed laser company based in San Clemente, CA, for the U.S. dental, dermatology, plastic surgery and anti-aging markets. Technology4Medicine will sell MedX Health’s newest laser product, Oralase(TM) immediately upon clearances from the Food and Drug Administration to dental offices. Oralase is a low level laser therapy (LLLT) exclusively designed for dentists to alleviate pain and accelerate tissue repair following dental procedures.

“This partnership fulfills a key component of our vision for growth and we are pleased to enter into this agreement with an exciting new company such as Technology4Medicine,” said Steve Guillen B.Sc., M.B.A., President & CEO, MedX Health. “As we move forward with our business plan to become the worldwide leader in light technology, MedX is committed to choosing the right partners to accelerate product distribution while continuing to develop superior products and explore new therapeutic opportunities for those products. We believe that Technology4Medicine is the right partner to penetrate the dental and other related markets in the United States through their specialized, experienced sales staff.”

“MedX is already well established in the rehabilitation market, offering innovative laser and light therapy products that have successfully treated pain, sports injuries and other conditions,” continued Guillen. “We believe our products can offer patients with acute and chronic wounds a non-invasive, drug free solution and we fully intend to pursue these indications aggressively.”

The terms of the agreement include MedX giving Technology4Medicine exclusive U.S. rights to sell Oralase and other MedX lasers that may be applicable in the dental, dermatology, plastic surgery and anti-aging markets. Increased levels of promotion are expected to cross over into these other large growth markets.

“This agreement helps put Technology4Medicine on the forefront of laser product distribution,” stated Jeff Jones, chief executive officer of Technology4Medicine. “We chose MedX as our partner to bring the many benefits of laser therapy to the US dental, aesthetic and other markets. This is a very impressive technology that will further establish our company in the dental industry with the best technology available. With Oralase, we believe we have a winning formula for quick uptake and use in this $1 Billion marketplace. The application of other MedX products in key U.S. markets such as aesthetic, anti-aging and dermatology, makes this a very attractive partnership.”

   About Oralase(TM)   -----------------  

Oralase is an ergonomically designed portable low level laser device that offers dental staff a proven, drug-free solution to eliminate pain and accelerate soft and hard tissue repair. Oralase is designed to effectively control pain and decrease swelling from invasive dental procedures as well as stimulate healing. MedX has submitted to the FDA for marketing approval.

MedX has developed products designed specifically for the dental market. These products consist of the Oralase 200mw portable dental laser with interchangeable intra-oral probes, an Oralase console system with three accessories treating both intra and extra -orally, controlled by the compact Model 1100 console, the MedX Home portable system for extra-oral treatment, and the Oralase portable.

The MedX dental product line offers dental staff a proven, drug free solution to eliminate pain and accelerate soft and hard tissue repair. There are over 325 dental research studies reporting positive effects of photon/light therapy in more than 90% of the trials. Treatments are fast and easy to set-up, 1-2 minute treatment times and excellent results for happier patients

MedX has developed and tested these products in dental clinics over the last two years and believes that Oralase products will be in demand by dentists as these products will provide the dentist with a competitive edge and a high return on investment. MedX estimates that there are 150,000 dental clinics in North America that can use these products resulting in a market size of $1.1 Billion.

   About Low-Level Laser Therapy   -----------------------------  

For more than 35 years, LLLT has been used in Europe, Australia, Asia and Russia for the treatment of pain and tissue repair. LLLT was approved in Canada in the early 1990’s and in the United States in 2002. LLLT uses a specific type of light to penetrate the skin’s surface and underlying tissues to stimulate the body’s natural repair processes. The result is faster healing and reduced pain, swelling and inflammation.

   About MedX Health Corp.   -----------------------  

MedX is a leading North American developer and manufacturer of phototherapy medical devices, including dental, rehabilitation and wound care products. MedX is the world’s only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for and bringing the non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX plans to use the proceeds from its recent public offering to expand its distribution network; support its marketing program; continue development of new dental, rehabilitation and wound care products; undertake research and development for wound care products; and for working capital purposes. In particular, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its “Photobandage”, a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

   About Technology4Medicine   -------------------------  

Technology4Medicine (http://www.t4med.com/), and itsTechnology4Therapy division, are committed to providing effective advanced technology to doctors and patients improving clinical outcomes, enhancing the quality of care, enhancing the patient experience and the clinician’s return on investment. Technology4Medicine is focused on ensuring customers have state-of-the-art technology and the highest quality of customer support, technical service and clinical training in the industry.

Technology4Medicine was founded in early 2008 by the former CEO/President, Jeffrey W. Jones, and Executive Vice President, Keith Bateman, of Biolase Technologies, Inc (BLTI). Jones and Bateman grew Biolase from less than $1 million in annual revenue to approximately $70 million and made Biolase the world leader in laser dentistry. Jones and Bateman also founded the World Clinical Laser Institute (WCLI) and grew it into the largest dental laser education organization in the industry.

   Photos available upon request.    The TSX Venture Exchange does not accept responsibility for the adequacy   or accuracy of this press release.   

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company’s future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, or “will be taken”, “occur”, or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

MedX Health Corp.

CONTACT: Steve Guillen, President & CEO, MedX Health Corporation, Phone:(905) 826-0766, Email: [email protected]; Jeff Jones, Chief ExecutiveOfficer, Technology4Medicine, Phone: (949) 361-1682, Email: [email protected];Terri Clevenger, Continuum Health Communications, Phone (203) 227-0209, Email:[email protected]

Asubio’s Biopten Wins Approval for Additional Indication

Asubio Pharma, one of the group companies of Daiichi Sankyo, has announced an additional indication for the inherited metabolic disease agent Biopten for the treatment of tetrahydrobiopterin responsive hyperphenylalaninemia.

Asubio’s Biopten is said to be a highly pure chemically synthesized form of the tetrahydrobiopterin (BH4) that occurs naturally in the human body. It treats hyperphenylalaninemia (HPA) patients by ameliorating the serum phenylalanine level.

Maruho marketed Biopten under a contract that expired at the end of June, 2008. From July 1, 2008 Daiichi Sankyo began marketing Biopten under a contract.

Genetics Tied To Sedentary Behavior

Mouse model studies point to genetic influence in active and sedentary behavior

The key to good health is to be physically active. The key to being active is to be born that way?

The well-documented importance of exercise in maintaining fitness has created the idea that individuals can manage their health by increasing their activity. But what if the inclination to engage in physical activity is itself significantly affected by factors that are predetermined? Two new studies suggest that the inclination to exercise may be strongly affected by genetics.

Controlled experiments into the effects of genetics on human activity have yet to be attempted, but recent studies on mice ““ the standard test species for mammalian genetics ““ have found genetic influences.

In a paper recently published in the journal Physiological Genomics, a team of researchers led by University of North Carolina at Charlotte kinesiologist J. Timothy Lightfoot announced that they had found six specific chromosomal locations that significantly correlate to the inheritance of a trait of high physical activity in mice, indicating that at least six genetic locations were affecting activity. Now, in a study forthcoming in The Journal of Heredity, the same team has identified 17 other genetic locations that also appear to control the level of physical activity in mice through interaction with each other, a genetic effect known as epistasis. Together, the located genes account for approximately 84% of the behavioral differences between mice that exhibit low activity levels and mice that show high activity traits.

“Can you be born a couch potato? In exercise physiology, we didn’t used to think so, but now I would say most definitely you can,” said Lightfoot.

The question of whether genetic influences can significantly affect activity in humans has never been rigorously studied, Lightfoot notes, but experiments with mice are indicating that the effect can be strong.

“The problem with the human literature in activity is that, up until recently, research has ignored the possibility that activity is regulated by biological as much as by environmental factors. What’s interesting is that there is a disconnect between the animal and the human literature in this ““ researchers haven’t been paying attention to the animal studies which, for example, have shown that that hormones affect activity.”

Lightfoot’s interest in the issue drew him to work with strains of mice that had markedly different behaviors when given an exercise wheel. A “high-active” strain scored notably higher than other strains in speed, duration and distance achieved in running than other strains, including one that was labeled as “aggressively sedentary” because of its consistent avoidance of activity.

At first, Lightfoot suspected that the difference was due to genetic factors affecting the way energy is used by muscle tissue because early genetic studies of the strains indicated that variation was present in genes known to affect metabolism. However, studies the team conducted on muscle tissue in the different mice failed to show a genetic effect that could cause a difference in muscle performance.

“We have done some gene chips on muscle tissue and we don’t see any differential expression between high-active and low-active animals in peripheral (muscle) tissue,” Lightfoot said. “So the suggestion that by over-expressing a glucose transporter we can increase activity doesn’t seem to be the explanatory factor.”

Subsequent studies have led the team to suspect that genetic differences are having a profound affect on mouse activity levels by causing significant differences in their brains.

“More and more what we are seeing is differences in brain chemistry. We are really convinced now that the difference is in the brain,” Lightfoot said. “There is a drive to be more active.”

The current studies interbred active and inactive strains of mice to re-sort the genes. The researchers tested the second generation (f2) of offspring for activity using three measurements — speed, endurance and distance ““ and found a range of significant differences among the new hybrid mice in their overall activity levels. The team then performed genetic tests on the mice and found significant correlations between differences in their genomes and the behavioral variations.

The team identified six locations on the mouse chromosome where differences had a strong relationship to activity, indicating at least six genes that individually can affect activity. A second genetic study found seventeen other genetic locations that were also having an effect on activity levels by interacting with each other.

While differences in activity could not be exclusively connected to genetics, a surprisingly large amount of the activity difference in the hybrids ““ about half ““ had a strong relationship to the specific genetic variations identified.

“We don’t know yet what the genes involved in activity are doing, but there is some strong suggestion that many of them may be involved in regulating dopamine,” Lightfoot noted. “In one sense it is very similar to a model for genetic influences on ADD.”

Lightfoot is professor in the Department of Kinesiology in UNC Charlotte’s College of Health and Human Services. Lightfoot’s co-authors for “An Epistatic Genetic Basis for Physical Activity Traits in Mice, ” forthcoming in The Journal of Heredity, are UNC Charlotte biologist Larry J. Leamy and geneticist Daniel Pomp from the University of North Carolina at Chapel Hill. Also cited in this release is “Quantitative Trait Loci for Physical Activity Traits in Mice,” which appeared in the February issue of Physiological Genomics and was co-authored by Lightfoot, Leamy, Pomp, M.J. Turner from the University of Sidney, and S.R. Kleeberger from the National Institute of Environmental Health Sciences.

On the Net:

Retirees Can Keep GM Plan Until They’re 65

By Patricia Anstett, Detroit Free Press

Jul. 17–Here are answers to commonly asked questions about health benefit changes for salaried General Motors Corp. retirees and their surviving spouses.

QUESTION: What changes did GM announce?

ANSWER: Beginning Jan. 1, retirees and spouses 65 or older and their dependents no longer will receive company group health benefits. Instead, they will receive a $300-a-month per retiree taxable contribution to their pensions. If a family has two GM retirees, the monthly contribution would be $600.

Q: What happens to spouses or salaried GM retirees who aren’t 65?

A: They will continue to be covered in GM’s salaried health plan until they turn 65, when they would lose coverage. Then each would need to find a Medicare plan.

Q: I am retired or retiring but not yet 65. When will my health care coverage be canceled?

A: The first day of the month that you turn 65. If you turn 65 on the first day of the month, coverage will cancel the first day of the prior month, consistent with Medicare eligibility guidelines.

Q. What are some of the most important things to consider when looking for a health plan, beyond what I want to spend?

A: The three essential issues are:

–Do you want to keep your current doctor network? If you do, you may have fewer plan choices.

–What prescription drugs do you take? Prescription drug coverage varies widely among insurance plans. So if you have to take a brand-name drug, check to see whether it is covered.

–Do you spend more than one month away from your Michigan home? If you do, you may be best with a company that has a wide provider network for emergency and urgent care visits. Schedule your routine prevention care and doctor visits when you are home in Michigan.

Q: I find Medicare coverage confusing. Give it to me in a nutshell.

A: Medicare provides basic hospitalization and some doctor and outpatient coverage. You have to buy a plan for everything else, such as prescription drug coverage. If you don’t travel much, you might find what you need in a Medicare Advantage plan, which provides a range of prevention and prescription coverage. But purchasing a Supplemental Medicare plan, also known as Medigap coverage, and a Part D prescription plan may be a more affordable options for others. Ask for price comparisons. Get the information in writing.

Q: I already have been diagnosed with a chronic health problem. Can I get a Medicare plan?

A: Yes, but it may cost you more if you wait too long to sign up. After about March 1, only Blue Cross Blue Shield of Michigan or Medicare Advantage plans must provide coverage to you if you have a preexisting health condition. Bills to require all insurers to cover people with preexisting conditions are being debated in the Legislature.

Contact PATRICIA ANSTETT at 313-222-5021 or [email protected].

—–

To see more of the Detroit Free Press, or to subscribe to the newspaper, go to http://www.freep.com

Copyright (c) 2008, Detroit Free Press

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

NYSE:GM,

Nurse Puts Veterans at Ease

By Conor Harrison, Kerrville Daily Times, Texas

Jul. 17–When Missy Rockwood makes her rounds at Kerrville’s VA Hospital, everyone on the fifth floor knows it. The smell of her fresh-baked cookies wafting down the halls is a dead giveaway.

“One big plus in being confined at the Kerrville VA Hospital is the privilege of getting to know a truly remarkable woman and role-model nurse, Missy Rockwood,” wrote the Rev. George Carlin in a letter to the Times. “When I first saw Missy, I thought Hollywood was filming a movie at the VA. She is a pure gift, an inspiration.”

Rockwood is no stranger to the military. Her father, Col. Conan G. Meyer, served in the Army. She is a self-described Army brat, who traveled constantly as a child around the country from base to base. Her husband, Andrew Rockwood, served as a commander in the Navy. And, her son, Charlie, recently graduated from the U.S. Military Academy at West Point.

“My dad and my son are my biggest inspirations,” Rockwood said. “My son was the starting outside linebacker for the Army football team, and I was the team mom for four years — go Army. I was the first official team mom in the history of the football program.”

After graduating from the University of the Incarnate Word in San Antonio, Rockwood worked as a nurse at Santa Rosa Hospital until 1992, when she moved with her family to Fredericksburg.

After taking a 15-year break to raise her four children — Charlie, Kirsten, Karen and Melcher — Rockwood returned to nursing in January at the VA Hospital.

“I enjoy my patients the most,” Rockwood said. “Talking to them, how they interact; they really look out for each other. I feel very much at home with these soldiers.”

Rockwood’s patients certainly agree.

“Missy loves her profession and is choosing a life of demanding and selfless service,” Carlin wrote.

She hears the same sentiments from her superiors at the VA.

“Missy is an asset to our nursing ward,” said Harriet Blackledge, associate chief of nursing services for geriatric and extended care. “She is always upbeat and positive.”

Rockwood feels the respect given to the nurses, and to each other, from her patients makes the long hours fly by.

“I have never seen a nurse disrespected,” Rockwood said. “These soldiers deserve to be treated like kings. It’s an honor for me to take care of these people who have served.”

When she is not at the VA doting on her patients, Rockwood enjoys visiting her daughter in New York, gardening and baking cookies for her next shift.

“I’m a type-A personality. Even when I’m at home, I’m thinking about and doing things for my guys,” Rockwood said. “I think all of the nurses at the VA feel the same way that I do about these soldiers. I want to be here as long as I can.”

—–

To see more of the Kerrville Daily Times or to subscribe to the newspaper, go to http://www.dailytimes.com/.

Copyright (c) 2008, Kerrville Daily Times, Texas

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Aethon’s Train-Themed Delivery Robot Available To Children’s Hospitals Nationwide

PITTSBURGH, July 17 /PRNewswire/ — Aethon Inc. today announced general availability of its train-themed “JR” autonomous mobile robot to children’s hospitals across the country and that Aethon will make a donation to the Make- A-Wish Foundation for each JR TUG that is deployed. The JR TUG is currently delivering equipment to children at Children’s Hospital of Wisconsin and medication to children in North Carolina at Carolinas Healthcare Systems in addition to the original implementation at UCSF.

Modeled after the title character in the children’s book “The Little Engine that Could,” JR was originally developed to help grant a wish for Jericho Rajninger, a seven-year old leukemia patient from Larkspur, California, and was donated to UCSF Children’s Hospital through the Make-A- Wish Foundation.

As part of his chemotherapy treatment Jericho had to take more than 4,000 pills. He realized that the prospect of all that medicine could be frightening for other children. Jericho believed that having the medications delivered by a robot modeled after a train might make the prospect of all those pills more pleasant.

“We were honored to make Jericho’s wish to help other sick children a reality,” said Aldo Zini, CEO of Aethon. “We are extremely pleased that the JR robots are being deployed in other children’s hospitals and hope that they will in some sense help sick children and their parents nationwide cope with a difficult experience.”

JR is based on Aethon’s TUG, a mobile autonomous robot that transports medical equipment and supplies. JR has drawers in its “caboose” from which medications can be drawn by nurses. The robot also features a conductor who speaks to children with the voice of legendary voice over actor Don LaFontaine. “Look out, here I come,””Thanks, from the bottom of my caboose,””Pardon my caboose, I’m turning around,””Engines revved and ready to go,” and “Choo choo, gotta run” are among the phrases JR speaks.

“Our JR TUG makes the delivery of equipment and supplies more efficient while offering some cheer to our young patients,” said Tom Lausten, director of Pharmacy Services at Children’s Hospital of Wisconsin. “In addition, staff is able to focus on patient care without having to worry about the logistics of delivery.”

Children’s hospitals interested in purchasing JR should visit http://www.aethon.com/contact.html.

About Aethon

Based in Pittsburgh, Pa., Aethon is a leader in affordable autonomous mobile robots for healthcare supply chain management. In healthcare, the company’s patented technology platform is redefining hospital supply chain logistics by automating the location, delivery and recovery of key assets. The net result of Aethon’s low-cost, easy-to-install, RFID-based asset utilization solution is improved caregiver efficiency and satisfaction, increased asset utilization, decreased equipment rentals, increased patient safety and satisfaction, and improved regulatory compliance. Nearly 100 hospitals nationwide have deployed Aethon’s TUG and HOMER robots. For more information, visit http://www.aethon.com/.

Aethon

CONTACT: Joe Costa, Aethon, +1-412-322-2975, [email protected]; LisaTristano, MARC USA PR, +1-412-562-1189, [email protected]

Web site: http://www.aethon.com/

Omnicell Helps Hospitals Reduce Inefficiencies and Inventory Costs in Hospital Speciality Areas With New Automated Wireless Supply Mobile Cart

MOUNTAIN VIEW, Calif., July 17 /PRNewswire-FirstCall/ — Omnicell, Inc., a leading provider of system solutions to acute healthcare facilities, today introduced its medical grade wireless Supply Mobile Cart that allows clinicians to access specialty supplies quickly, securely and efficiently from any location at any time. When using this new battery powered, automated dispensing Supply Mobile Cart from Omnicell, hospitals benefit from reduced inventories, an increase in captured charges as well as a more accurate and automated replenishment of rolling stock.

“Having a supply cart that is easier to use and easier to move meets the unique needs of clinicians in specialty areas such as operating rooms, cath labs, and emergency departments,” said Gary Rakes, Director of Materials Management, St, Patrick’s Hospital, Missoula, MT. “Features such as automatic monitoring of supply usage to ensure constant availability of needed items allows for improved cost management and efficiency for high priced items often stocked here.”

Specific uses of the Supply Mobile Cart from Omnicell may include: emergency supplies, suture cart, Port-a-Cath(R) cart, ventriculo-peritoneal cart (VP shunt cart), peripherally inserted central catheter cart (PICC line cart), pace maker cart (IACD), orthopedic hardware or aneurysm clip cart. The cart can also be used as a stent cart or for securing other high cost supplies that need to be moveable.

“Current hospital supply carts are inefficient and require manual processes that can result in inaccurate or lost charges as well as over and under stocking,” said Robert Mullenger, group product line manager, Omnicell, Inc. “By combining an automated supply process with a wireless mobile cart, we are offering care providers a tool that is easier to use and easier to move that results in increased patient safety and work efficiency.”

The wireless Supply Mobile Cart from Omnicell reduces costs by automating both the replenishment of supplies and the billing process so that inventories are minimized and all charges are captured accurately. To improve patient safety and regulatory compliance, automated lot, serial number and expiration date tracking increases dispensing accuracy and reduces the possibility of errors. Guiding light technology includes both drawer location light and product dedicated lights that guide the user to the selected supplies. In addition, clinical based workflow tracks supplies in the operating room (OR) from central sterile, OR core, OR suites and rolling stock; and in the cath lab, procedure based workflow tracks supplies to the physician, case type, technician and patient.

For more information please visit the Omnicell booth #1309 at the AHRMM08 annual conference and exhibition at the Henry B. Gonzalez Convention Center, July 20-23, or visit http://www.omnicell.com/.

About Omnicell

Omnicell, Inc. is a leading provider of systems targeting patient safety and operational efficiency in healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.

Omnicell’s medication-use product line includes solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from complete automation systems for the central pharmacy to nursing unit and bedside dispensing cabinet systems. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.

Our supply product lines provide a healthcare institution with fast, effective control of costs, capture of charges for payer reimbursement, and timely reorder of supplies. Products range from high-security closed-cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room. For more information, visit http://www.omnicell.com/.

Omnicell, Inc.

CONTACT: Deborah Reinert of Omnicell, Inc., +1-650-251-6403,[email protected]; or Linda Capcara of LVA Communications,+1-480-229-7090, [email protected], for Omnicell, Inc.

Web site: http://www.omnicell.com/

EDAP Announces Initial Ablatherm-HIFU Treatments At Premiere M.D. Anderson Cancer Center in Ongoing Phase II/III Clinical Trial

LYON, France, July 17, 2008 (PRIME NEWSWIRE) — EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that urologists at the University of Texas M.D. Anderson Cancer Center have treated their first two localized prostate cancer patients with Ablatherm-HIFU (high intensity focused ultrasound). The prestigious center is one of 13 Ablatherm sites participating in ENLIGHT, EDAP’s ongoing Phase II/III clinical trial to evaluate the minimally invasive, robotized treatment in patients with localized prostate cancer.

John F. Ward, M.D., F.A.C.S., Assistant Professor, Department of Urology at M.D. Anderson Cancer Center, and Principle Investigator of the trial at the Center said, “We are delighted to participate in EDAP’s ENLIGHT trial, particularly because M.D. Anderson is always looking at novel treatment approaches with the potential to provide greater efficacy, fewer side effects, and better quality of life for cancer patients. We see great promise for Ablatherm-HIFU as a minimally invasive treatment that targets localized prostate cancer, which could effectively treat the disease and allow patients to resume their day-to-day activities with minimal or no downtime. ENLIGHT provides an opportunity to rigorously evaluate this potential. “

Marc Oczachowski, EDAP’s Chief Executive Officer, commented, “We are fortunate to have the world renown M.D. Anderson Cancer Center participating in the ENLIGHT trial which has received Investigational Device Exemption by the FDA. The center’s initial treatments with Ablatherm-HIFU mark a significant milestone in our development program, and additional patients have been scheduled to receive our minimally invasive treatment in the coming weeks. Attracting leading American cancer centers is part of our strategy to gain HIFU visibility and potentially accelerate patient enrollment at all participating sites as we advance towards submission for FDA approval in the U.S. We are confident that the validation from our participating sites, in conjunction with ongoing momentum from our marketing and referral program, continues to generate increased patient awareness of HIFU.”

About M.D. Anderson Cancer Center

M.D. Anderson, one of the world’s most respected cancer centers, has built a reputation for excellence over the past 60 years through its devotion to patient care, and clinical and basic science research by educating the next generation of physicians and striving to prevent human malignancy. U.S. News and World Report’s “America’s Best Hospitals” survey ranked M. D. Anderson as the #1 hospital in the nation for cancer care in 2008. The magazine has given M.D. Anderson the number one ranking in seven of the past eight years. This same survey has also consistently ranked M. D. Anderson’s Department of Urology as one of the top 10 Urology centers in the Nation.

About the ENLIGHT Study

The Phase II/III prospective non-inferiority study is designed to evaluate the safety and efficacy of EDAP’s Ablatherm-HIFU system versus Cryotherapy for the treatment of low-risk, localized prostate cancer. The clinical trial is currently enrolling men over age 60 diagnosed with clinical stage T1a, b, or c or T2a localized prostate cancer. The primary outcome measure of the trial is statistically significant reduction and stability of the prostate-specific antigen (PSA) throughout a 24-month follow-up period. Details of the study and background on Ablatherm-HIFU can be found by searching for “Ablatherm” online at www.ClinicalTrials.gov.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com and http://www.hifu-planet.com or http://www.urotoday.com/HIFU.

This news release was distributed by PrimeNewswire, www.primenewswire.com

 CONTACT: EDAP TMS SA          Investor Relations / Legal Affairs:          Blandine Confort          +33 4 72 15 31 72          [email protected]                    The Ruth Group          Investors:          R.J. Pellegrino          646-536-7009          [email protected] 

L&M Healthcare Communications LLC Offers Promotional Speaker Programs Compliant With Revised PhRMA Code

MOUNTAINSIDE, N.J., July 17 /PRNewswire/ — L&M Healthcare Communications LLC, an independent, full-service medical education company, applauds PhRMA for recognizing the importance of responsible and compliant management of promotional speaker programs. L&M has been, and will continue to be, a provider of PhRMA compliant medical education and speaker programs.

L&M operates a customized speakers’ bureau which manages and tracks more than 5,000 speaker programs. Utilizing a proprietary database and highly trained staff, L&M meets the individual needs of each client, while strictly conforming to the constantly changing regulatory environment.

“The newly revised PhRMA Code highlights the value of a knowledgeable and experienced team to manage promotional speaker programs and medical education activities,” said Lenny LaManna, DPM, Partner at L&M Healthcare Communications. “In this constantly-changing regulatory environment, L&M’s commitment to managing compliant programs for our clients will continue to be a priority.”

The staff at L&M have nearly 100 years of experience in healthcare communications in a variety of therapeutic areas including central nervous system diseases, dermatologic conditions, wound healing, oncology, women’s health, gastroenterology, urology and cardiology. This experience, plus the company’s commitment to client service, is what differentiates L&M from other agencies.

“Adaptability and experience are the cornerstones of great medical education,” notes Adam Margolis, Partner at L&M Healthcare Communications. “Our team is well versed in the PhRMA Code as well as other industry regulations, and we will continue to ensure that our clients’ activities are effective and educational while being grounded in sound compliance with the latest version of the Code.”

About L&M Healthcare Communications LLC

L&M Healthcare Communications LLC is an independent, full-service medical education company with offices in Mountainside, New Jersey and Milwaukee, Wisconsin. Core services include thought-leader/advocacy development, core launch educational materials, speakers’ bureau and publications.

L&M Healthcare Communications LLC

CONTACT: Adam Margolis, Partner, L&M Healthcare Communications,+1-908-588-9107, Fax +1-908-232-3051, [email protected]

Web site: http://www.lmhcare.com/

Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery

SOUTH SAN FRANCISCO, Calif., July 17 /PRNewswire-FirstCall/ — Anesiva, Inc. today announced that it has begun a Phase 2 clinical trial of Adlea(TM), the company’s long-acting, site specific, non-opioid drug candidate for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

Adlea is currently in two pivotal Phase 3 trials in the U.S.: one in total knee replacement surgeries and one in bunionectomy surgeries. An additional Phase 2 Adlea trial is in progress in total hip replacement surgeries. These trials are among those intended to support an Adlea label indication for the management of acute pain following orthopedic surgery.

The Phase 2 arthroscopic shoulder surgery trial is being conducted in South Korea. Unlike the United States, where the procedure is often conducted on an outpatient basis, arthroscopic shoulder surgery patients in South Korea are routinely hospitalized for up to two days, thus allowing more extensive near-term follow-up.

“We believe Adlea holds promise for treating pain associated with a number of orthopedic surgical indications, and may reduce the need for other pain treatments such as opioids,” said Michael L. Kranda, Anesiva’s president and chief executive officer. “As we pursue a broad indication of management of post-surgical pain following orthopedic procedures, each specific procedure that we can evaluate will add to the breadth of available data for Adlea.”

Arthroscopic surgery is performed through small incisions using an arthroscope, or camera, to visualize the inside of a joint. Through the incisions, a surgeon inserts a camera and small instruments to perform the procedure. According to the American Academy of Orthopedic Surgeons, about six million Americans go to the doctor each year for shoulder pain, dislocation, or other shoulder problems and up to 500,000 arthroscopic shoulder surgeries are performed in the United States each year.

This multicenter, randomized, double-blind, dose-escalating, placebo-controlled study is evaluating the safety, tolerability, efficacy, and pharmacokinetics of a single dose of Adlea administered via injection following surgical closure of the wound. The trial is designed to enroll 74 patients.

Anesiva announced approval of its investigational new drug application for Adlea in South Korea in June 2008.

How Adlea May Address the Need for Long-Duration, Well-Tolerated Pain Relief

Adlea is a long-acting, non-opioid drug with the potential to provide pain relief for weeks to months after a single localized treatment. Its novel mechanism of action results in site-specific analgesia, which has the potential to reduce the use of and minimize the side effects associated with systemically administered analgesic drugs, such as opioids and NSAIDs.

Adlea is a highly purified form of capsaicin (derived from chili peppers) that acts primarily on C-fiber neurons, which transmit long-term pain, by binding to and desensitizing the TRPV1 pain receptors. This leads to a prolonged, reversible and localized desensitization of the pain fibers. The drug generally has a short half-life of 1 to 2 hours, and is undetectable in the blood after 24 hours.

Adlea’s short duration of systemic exposure relative to the longer duration of analgesia may offer a safe, additive treatment option in the management of post-surgical orthopedic pain, as well as pain due to moderate to severe osteoarthritis. In clinical trials to date, adverse events have been similar in patients receiving Adlea or placebo.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company’s first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18.

The next product in Anesiva’s pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva’s leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com/.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,””estimate,””project,””budget,””forecast,””anticipate,””intend,””plan,””may,””will,””could,””should,””believes,””predicts,””potential,””continue,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, and our regulatory approval strategy for Adlea. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva’s annual report on Form 10-K for the year ended December 31, 2007 and most recently quarterly report on Form 10-Q.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Anesiva, Inc.

CONTACT: Carol DeGuzman, Sr. Dir., Investor Relations of Anesiva, Inc.,+1-650-624-9600, [email protected]; or Media, Carolyn Wang of WeissCommPartners, +1-415-946-1065, [email protected], for Anesiva, Inc.

Web site: http://www.anesiva.com/

Omnicell OptiFlex CL Automates Cath Lab Supply Tracking at St. Patrick Hospital

MOUNTAIN VIEW, Calif. and MISSOULA, Mont., July 17 /PRNewswire-FirstCall/ — Omnicell, Inc. a leading provider of system solutions to acute healthcare facilities, and St. Patrick Hospital and Health Sciences Center, a 237 bed facility in Missoula, Montana, today announced the successful installation of an interface between the hospital’s Omnicell OptiFlex(TM) CL system and its Philips Series IV physiomonitoring and information system.

“The OptiFlex CL system automates our supply reorder process, giving us greater control and accuracy in ordering to ensure that supplies are always on hand,” said Steve Hartigan, lead cath lab technician at St. Patrick Hospital and Health Sciences Center. “In addition, we benefit from a reduction in manual work that frees our staff to spend more time on patient-specific care.”

St. Patrick Hospital and Health Sciences Center has been using the OptiFlex CL system in its cardiac cath labs to facilitate real-time automated supply point-of-use data collection. The powerful OptiFlex CL software seamlessly interfaces with the Philips cath lab monitoring and charting software, further reducing the need for manual key entries and automatically populating its American College of Cardiology database with accurate supply information. The complete integrated system made possible by OptiFlex CL software allows cath lab management staff to evaluate the overall performance of the hospital on cardiac cath lab cases by tracking supplies and procedures to a physician for cost management and automated charge capture.

“Tracking supplies in hospital specialty areas like the cath lab at St. Patrick is increasingly tied to patient safety and clinical processes,” said Robert Mullenger, group product line manager, Omnicell. “A cath lab manager benefits from the OptiFlex system because it provides one solution to track all supplies accurately, including implants; and provides interfaces to hospital systems that they depend on.”

For more information please visit the Omnicell booth #1309 at the AHRMM08 annual conference and exhibition at the Henry B. Gonzalez Convention Center, July 20-23, or visit http://www.omnicell.com/.

About Omnicell

Omnicell, Inc. is a leading provider of systems targeting patient safety and operational efficiency in healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.

Omnicell’s medication-use product line includes solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from complete automation systems for the central pharmacy to nursing unit and bedside dispensing cabinet systems. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.

Our supply product lines provide a healthcare institution with tools to obtain faster, more effective control of costs, capture of charges for payer reimbursement, and timely reordering of supplies. Products range from high-security closed-cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room. For more information, visit http://www.omnicell.com/.

About St. Patrick Hospital and Health Sciences Center

St. Patrick Hospital and Health Sciences Center is a medical center under the sponsorship of Providence Health & Services. A not-for-profit health system committed to providing a comprehensive array of services to meet the needs of communities across five states, including Alaska, Washington, Montana, Oregon and California.

Providence Health & Services includes 26 hospitals, more than 35 non-acute facilities, physician clinics, a health plan, a liberal arts university, a high school, approximately 45,000 employees and numerous other health, housing and educational services. The system office is located in Seattle, Washington.

Providence Health & Services in Alaska, Washington, Montana and Oregon are sponsored by the Sisters of Providence religious community.

St. Patrick Hospital is a 237 licensed hospital bed facility in Missoula, Montana with a 17 county service area. St. Patrick Hospital is recognized for excellence in patient care in such areas as cancer, heart, neuroscience, orthopedics, women’s health and rehabilitation services.

Omnicell, Inc.

CONTACT: Deborah Reinert of Omnicell, Inc., +1-650-251-6403,[email protected]; or Linda Capcara of LVA Communications,+1-480-229-7090, [email protected], for Omnicell, Inc.

Web site: http://www.omnicell.com/

Spotsy Nursing Center is Sold: Carriage Hill Nursing Home Has Been Sold to a Partnership of Two Roanoke Companies

By Jim Hall, The Free Lance-Star, Fredericksburg, Va.

Jul. 17–Carriage Hill Rehabilitation and Nursing Center, the region’s second largest nursing home, has been sold.

Officials of MediCorp Health System said yesterday that two Roanoke companies have agreed to pay $13.35 million for the Spotsylvania County home. The transfer is expected within 90 days.

Commonwealth Care and Smith/Packett Med-Com will share equally in the ownership of the real estate. Commonwealth Care will operate the facility.

Employees, residents and families learned about the sale at meetings Tuesday and yesterday.

Deborah Petrine, president of Commonwealth Care, said yesterday that Carriage Hill will continue to operate as a nursing home. The company also will retain its Alzheimer’s unit and its rehabilitation wing, she said.

The staff of 132 people will keep their jobs at their current salaries, she added. Nicole Threatt has agreed to stay on as administrator, and Rod Coleman will remain as director of nursing, she said.

“We think it’s a very quality facility,” Petrine said.

Carriage Hill is one of five nursing homes in the region and the only one that is locally owned. It opened 22 years ago off State Route 3. At present, 101 people live there.

Both Commonwealth Care and Smith/Packett are privately held, for-profit companies. MediCorp is a nonprofit company and the parent company of Mary Washington Hospital and the planned Stafford Hospital Center.

Founded in 1982, Smith/Packett bills itself as one of the nation’s largest developers of senior housing.

In March, Smith/Packett received permission from the Stafford Board of Supervisors to develop a 22-acre retirement community on Berea Church Road.

The project will have 436 units, divided among condominiums, independent-living apartments, assisted-living units and a nursing home.

Commonwealth Care, founded 7 years ago, operates seven other nursing homes in Virginia, with an eighth soon to open. Its closest homes are in Manassas and Gainesville.

The two companies have worked together for more than a decade.

MediCorp began considering offers for Carriage Hill earlier this year.

Walt Kiwall, executive vice president and chief operating officer, said yesterday the company set three conditions for prospective buyers:

That the home continue as a long-term care facility.

That residents receive quality care.

That employees be treated fairly.

MediCorp chose Commonwealth Care and Smith/Packett from among several bidders. MediCorp’s board of trustees approved the sale last week.

Carriage Hill ran into regulatory trouble last year. The home lost its Medicare and Medicaid funding in May after a series of inspections found numerous problems, including the apparent accidental strangling of an 83-year-old resident. The home was reinstated to both programs earlier this year.

Despite the loss of government funding for seven months, the home had revenue of $6.3 million last year, according to MediCorp’s audit.

The home remained open with about 100 residents, and expenses totaled $10.8 million. The loss for the year was $4.5 million, according to the audit.

In most years, Carriage Hill showed a small profit on revenue of about $10 million, said Fred M. Rankin III, MediCorp’s president and CEO. Annual revenue for MediCorp and all of its subsidiaries is about $500 million.

“It was an important part of our operation but a small part,” Rankin said.

Rankin said the regulatory troubles and the work needed to restore Carriage Hill to the government programs taught MediCorp officials that the long-term care business is unique.

“The lesson for us is that it’s a different business,” Rankin said. “The best we could do was find a company that knows that business.”

—–

To see more of The Free Lance-Star or to subscribe to the newspaper, go to http://fredericksburg.com/flshome.

Copyright (c) 2008, The Free Lance-Star, Fredericksburg, Va.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Bombay:524794,

Chinese TV Drama ‘Cherry Love’ Planned

Greater China Media and Entertainment Corp. says it has entered into a contract with Kingjoy Vision Inc. to produce a TV series called Cherry Love.

Greater China is an integrated professional media and entertainment company and Kingjoy is a movie and film producing company.

The two parties Wednesday announced plans to jointly produce the 27-episode, small-screen romantic drama, Cherry Love, which is to start shooting next June.

The total investment is estimated to be $3.8 million, with each company paying half.

After the completion of the show, GCME said it will enjoy exclusive copyrights in mainland China, while Kingjoy will be entitled to the copyright in Hong Kong, Taiwan and Macao.

The lead role in Cherry Love will be played by Takeshi Kaneshiro, a Japanese-Taiwanese actor, however, the show’s lead actress has yet to be cast.

TV dramas centering on finding and keeping true love are still the mainstream on TV, especially in Asia, Jake Wei, chief executive offcier of GCME, said in a statement. With the incredible cast and crew, I believe that this TV series will enjoy high ratings and bring our investors a great deal of success.

BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial

SAN ANTONIO, July 17 /PRNewswire/ — BioNumerik Pharmaceuticals, Inc. (“BioNumerik”) today announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating in a Phase II clinical trial of Tavocept(TM) showed a survival increase of approximately 198 days (6.5 months). The trial observations included an approximate 40% reduction in mortality for adenocarcinoma patients receiving Tavocept. The percentage of adenocarcinoma patients in the Tavocept group who were alive after 12 months (One-year survival) was 58% compared to 37% for adenocarcinoma patients in the chemotherapy only group. The median survival time for all non-small cell lung cancer (NSCLC) patients in the trial showed an increase of approximately one month for patients receiving Tavocept. This is the second Tavocept clinical trial where this pattern of survival increase has been observed. Tavocept is an investigational new drug with potential for oncology and non-oncology indications that was originated and developed by BioNumerik.

The randomized Phase II clinical trial (the “U.S. Tavocept Trial”) was performed at multiple sites in the U.S. and involved 151 patients with advanced NSCLC who received the chemotherapy drugs docetaxel (sold under the brand name Taxotere(R)) and cisplatin every two weeks. Approximately half of the patients received Tavocept along with chemotherapy, while the other half received chemotherapy alone.

Additional observations from the U.S. Tavocept Trial included a lower level of treatment discontinuation due to adverse events for the Tavocept group as well as a lower frequency of serious (grade 3 and 4) treatment related adverse events. A substantial reduction in chemotherapy-induced renal (kidney) toxicity and nausea/vomiting was also observed in the Tavocept group.

“The observations from the U.S. Tavocept Trial are extremely encouraging,” said Frederick H. Hausheer, M.D., chairman & chief executive officer of BioNumerik. “The increase in patient survival with Tavocept compares favorably to observations seen for other cancer drugs. For example, the cancer drug Avastin(R) (also known as bevacizumab) was approved in the United States to treat lung cancer while exhibiting a survival increase of approximately two months when used with a standard chemotherapy treatment regimen. Recent data for the cancer drug Erbitux(R) (also known as cetuximab) demonstrated a survival increase of about 1.2 months compared to chemotherapy alone in patients with advanced epidermal growth-factor receptor (EGFR)- detectable non-small-cell lung cancer.”

Earlier this year, BioNumerik and ASKA Pharmaceutical Co., Ltd. (“ASKA”) reported results from a randomized, multi-center Phase III clinical trial of Tavocept that also indicated a survival increase in adenocarcinoma and non- small cell lung cancer patients. That clinical trial (the “Japan Tavocept Trial”) was conducted in Japan by ASKA and involved 182 advanced non-small cell lung cancer patients who received the chemotherapy drugs paclitaxel and cisplatin every three weeks. Half of the patients in the trial received Tavocept along with their chemotherapy, while the other half received a placebo and chemotherapy. The results from the Japan Tavocept Trial demonstrated an observed increase in median survival time of approximately 138 days (4.5 months) for adenocarcinoma patients receiving Tavocept as compared to those receiving placebo. For all non-small cell lung cancer patients participating in the Japan Tavocept Trial, the median survival time observed for patients receiving Tavocept was approximately 40 days longer than the median survival time for patients receiving placebo.

Dr. Hausheer added: “The results from the U.S. Tavocept Trial are important because they confirm and expand on the results from the Japan Tavocept Trial, and represent the second time we have seen this type of a survival increase. The increased survival observed in both the U.S. and Japan Tavocept trials appears to involve the novel pharmacological mechanisms of Tavocept, which appear to be insensitive to ethnicity or region. In addition, both trials showed a reduction in chemotherapy-induced toxicities in the Tavocept group with no dose limiting toxicity observed for Tavocept in either trial. These observations support that Tavocept has the potential to prevent common and serious side effects due to chemotherapy without any substantial dose-limiting toxicity of its own. Based on these results, we are planning to pursue confirmatory Phase III development of Tavocept in the United States and Japan.”

The U.S. Tavocept Trial observations occurred in a patient population that was predominantly non-Asian, compared to the Japan Tavocept Trial where the patient population was entirely Asian. This indicates that the potential survival increase observed for adenocarcinoma patients receiving Tavocept appears to occur across different ethnic groups. Since the U.S. Tavocept Trial involved cisplatin and the taxane drug docetaxel while the Japan Tavocept Trial involved cisplatin and the taxane drug paclitaxel, BioNumerik has also now observed this pattern of a Tavocept increase in survival in first-line non-small cell lung cancer treatment regimens utilizing two different types of taxane chemotherapy drugs.

“It is also important to consider that the U.S. Tavocept Trial was a Phase II clinical trial involving a relatively small number of patients and that the observations regarding survival and toxicity reduction related to secondary analyses and endpoints for the trial,” added Dr. Hausheer. “In addition, the survival analysis in adenocarcinoma patients was not prespecified. The findings are quite encouraging, but these results will require verification in further Phase III clinical studies.”

BioNumerik holds exclusive rights to Tavocept for all territories outside of Japan. BioNumerik has granted KI Pharmaceuticals, Inc., a joint venture formed by BioNumerik and ASKA, the exclusive right to develop, market, distribute and sell Tavocept in Japan.

About Adenocarcinoma:

Adenocarcinoma is a type of cancer that can occur in cells that are in organs such as the lung, colon, prostate and breast. Adenocarcinoma is the most common type of lung cancer, making up approximately 30% to more than 50% of all cases. The incidence of adenocarcinoma of the lung appears to be increasing.

About BioNumerik:

BioNumerik Pharmaceuticals, Inc., based in San Antonio, Texas, is focused on the discovery, development and commercialization of novel drugs for the treatment of cancer and for cancer supportive care. BioNumerik currently has two drug candidates, Karenitecin(R) and Tavocept(TM), in late-stage clinical development. BioNumerik has eight additional drug discovery research programs, and has generated a patent portfolio of more than 450 patents and pending patent applications worldwide.

    Contact:    BioNumerik Pharmaceuticals, Inc.    Public Relations Department    (210) 614-1701, ext. 500    email:  [email protected]  

BioNumerik Pharmaceuticals, Inc.

CONTACT: BioNumerik Pharmaceuticals, Inc., Public Relations Department,+1-210-614-1701, ext. 500, [email protected]

Web site: http://www.bionumerik.com/

Parkinson’s Drug May Cause Addictive Behavior

When Tammy Rothwell started taking a prescription drug called Mirapex for the symptoms of her Parkinson’s disease, she thought she had finally found peace after 25 years.

But as Rothwell’s muscle tremors faded under the medication, a new problem arose.

Rothwell, who said she had never gambled and was careful with her money before starting Mirapex, began compulsively spending $200 a day on scratch-off lottery tickets and making irrational purchases like 100 tubes of lipstick. The habits escalated so rapidly, Rothwell said, she ran through more than $70,000 in two years.

“It was night and day. There was another person there,” Rothwell said. “I was manic to the point where there was another person inside of me. I knew that I could not do anything about it, I had no control whatsoever, and I’m a control freak.”

Neurologists have long observed dramatic changes in the behavior of patients receiving treatment for Parkinson’s disease, with some developing gambling problems, heightened sexual interest or compulsive spending and eating habits where there had previously been no sign of such disorders.

Now, the largest study ever conducted on the phenomenon has found that more than 13 percent of patients taking a particular class of drug called dopamine agonists, sold under brand names including Mirapex and Requip, suffer from at least one of four serious behavioral addictions.

The results, presented in June at the International Congress of Parkinson’s Disease and Movement Disorders conference in Chicago, could change the way neurologists choose to treat certain patients with movement disorders like Parkinson’s.

But the observation that a drug may trigger dramatic behavioral changes in some people _ changes many said switched off almost immediately when they stopped taking the drug _ also offers new evidence that issues like gambling and shopping addictions have roots in the balance of chemicals in the brain.

“It offers a real window that’s hard to duplicate in other populations; it’s hard to make a gambling problem or an eating problem go away relatively quickly,” said Dr. Daniel Weintraub, assistant professor of psychiatry at the University of Pennsylvania and lead author on the study. “I think this research really opens up a lot of interesting questions, not only for Parkinson’s disease but perhaps for the general population as well.”

Parkinson’s disease, marked by motor symptoms such as muscle tremors, rigidity and slow, uncoordinated movements, results from the depletion of the neurotransmitter dopamine in the brain. As such, most drugs given to Parkinson’s patients are meant to replace the missing dopamine and restore normal motor function.

Yet dopamine controls more than motor function; it also plays a role in the brain’s response to rewards like eating, drugs and sex. Powerfully activating the dopamine system with drugs could cause people to find such stimuli more rewarding than normal, inducing them to repeat behaviors to the point of physical or financial harm.

“It’s a good thing to have sex, a good thing to eat, good thing to be risky,” said Celeste Napier, professor of pharmacology at Rush University Medical Center. “But if these natural good things get exaggerated by having so much dopamine in critical parts of brain, that may enhance impulsivity and compulsive behaviors.”

But other researchers caution that the brains of Parkinson’s patients are changed drastically by the disease, and the link between dopamine and compulsive behaviors may not be so clear-cut in the general population. That only a subset of Parkinson’s patients on dopamine agonists develop behavioral addictions also suggests the presence of unknown factors that make certain brains more sensitive to the drugs than others.

“The whole issue of how Parkinson’s disease presents the biology of this is not clear yet,” said Dr. Un Jung Kang, professor of neurology at University of Chicago, “but it really provides a fascinating neurobiological angle.”

The study, which looked at more than 3,000 patients from 46 medical centers in the United States and Canada, found that Parkinson’s patients on dopamine agonists are nearly three times more likely to have at least one impulse control disorder compared to patients receiving other treatments.

The study was funded by Boehringer Ingelheim, the German pharmaceutical company that produces Mirapex, one of the most commonly prescribed drugs for Parkinson’s disease.

Kate O’Connor, spokeswoman for the company, said that warnings about the potential development of compulsive behaviors have been included with the drug’s package insert for several years.

“We do feel we are already making people aware so they can watch for any such behavior in patients, so that choices can be made about treatment,” O’Connor said. “There is nothing about the study that told us anything should be changed in the way the drug is used.”

But while neurologists agreed that drugs like Mirapex have helped thousands of Parkinson’s sufferers control their symptoms, the occurrence of such severe behavioral side effects have made them cautious about their use.

Dr. Eric Ahlskog, a neurologist at the Mayo Clinic who has treated Parkinson’s patients for 25 years, said he no longer is comfortable starting patients on dopamine agonists after three patients in his practice last year developed significant gambling and sexual problems.

One patient, a middle-aged man, suddenly began expressing hypersexuality and was arrested for publicly exposing himself.

“If you get hit in the head often enough, you learn to look up,” Dr. Ahlskog said. “You realize it’s such a tragedy … whatever good they get from the drug is far overshadowed by these tragic developments in their life.”

Other neurologists said they won’t stop prescribing the dopamine agonists but have started using smaller doses and closely monitoring patients for the onset of harmful addictions.

Because many patients don’t associate their new habits with the drug, or might be embarrassed to bring such problems up with their neurologist, some doctors now ask patients and their families about compulsive behaviors like gambling and sexual fantasies as part of routine patient checkups.

“Some patients think they’re morally weak people, they think it’s their fault,” said Dr. Kathleen Shannon, a neurologist at Rush University Medical Center. “I sometimes really have to convince people it’s the drug. But as soon as people come off of it they realize have a whole different feeling about gambling … it’s really an amazing observation.”

Cindy Horn of Bloomingdale, Ill., said she didn’t associate the drug she was taking for her Parkinson’s symptoms – Requip, manufactured by Glaxo SmithKline – with any behavioral issues until her doctor asked about her spending habits.

The question made her realize that her spending had spiraled out of control while on a high dose of the drug, spending nearly $30,000 and maxing out several credit cards on what she now recognizes were irrational, impulsive purchases of clothing, appliances and vacation packages.

“Instead of buying just one, I would buy 10,” Horn said. “My children were trying to put the brakes on, but no one could tell me what to do. I didn’t know who it was; it was somebody else.”

On the Net:

Assurant Health Appoints SVP and General Counsel

Assurant Health, a provider of individual medical, small group and specialty health insurance products, has named Jennifer Kopps-Wagner as its new senior vice president and general counsel.

Ms Kopps-Wagner joined Assurant Health in 1999, holding a succession of positions in the company’s legal department. In her most recent role as the vice president of legal, she provided legal support and counsel for Assurant Health’s Individual Medical and Worksite and Specialty Products product lines, as well as the operations area.

Ms Kopps-Wagner currently serves as the secretary for the Assurant Health Foundation. She has earned her bachelors degree from Alverno College in Milwaukee and her law degree from the University of Wisconsin.

Don Hamm, president and CEO of Assurant Health, said: “As we continue to serve the needs of our customers, business partners and shareholders, Jennifer’s high level knowledge and skills are a true asset. She brings a great deal of experience to this role and I am extremely pleased to make this announcement.”

Legislation Would Give Feds Power to Force Food Recalls

By Misti Crane, The Columbus Dispatch, Ohio

Jul. 17–The federal agencies

responsible for keeping

the food on your table safe from contaminants including E. coli and salmonella have no authority to force product recalls.

Instead, the Food and Drug Administration and Department of Agriculture rely on the good will of slaughterhouse operators, grocery-store executives and others.

However, proposals in both chambers of Congress aim to give the government the power to force recalls. The authors of the bills have asked House and Senate leaders to speed passage in light of recent outbreaks.

Sen. Sherrod Brown, an Ohio Democrat behind the Senate proposal, said he expects wide support and that several public-health bills currently under consideration could provide a vehicle for the change.

Brown pointed out that about 5,000 people die each year from tainted food in the United States.

“We must preserve the integrity of the U.S. food supply,” he said.

The proposal drew quick opposition from the American Meat Institute, the largest beef industry group, representing about 200 packers and processors.

“When companies need to do a recall, they do,” said spokeswoman Janet Riley. “We benefit by executing recalls as fast as we can when they occur.”

Those seeking federal changes, including many food-safety experts, say two recent outbreaks have highlighted gaps in oversight and prompted calls for changes, including mandatory recalls.

The one closest to home began in June with a cluster of central Ohio illnesses caused by E. coli O157:H7, a potentially lethal bacteria that live in cow intestines.

In recent weeks, that outbreak has grown to include at least 44 people in five states and prompted Nebraska Beef to recall more than 5 million pounds of meat and Kroger to recall an unknown amount.

The other, a national

salmonella outbreak, has sickened at least 1,167

people since April.

In 10 outbreaks since 2003, 217 Ohio residents were sickened, 66 of whom were hospitalized, and one died, according to the Ohio Department of Health.

Private companies aren’t always as quick as they should be in issuing recalls and executives sometimes try to “sweep it under the rug,” Brown said.

“I want to make these companies more responsible.”

FDA officials have said they want recall authority.

The bills follow a recent report from the U.S. Government Accountability Office that found that several other countries and the European Union have stricter, stronger food-safety systems.

Mandatory recall authority and the ability to trace food from the farm to the table are key elements in strengthening the system, the accountability office found.

Although the number of recalls appears to be declining, the size of those recalls is growing, according to the office’s report.

[email protected]

—–

To see more of The Columbus Dispatch, or to subscribe to the newspaper, go to http://www.columbusdispatch.com.

Copyright (c) 2008, The Columbus Dispatch, Ohio

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

NYSE:KR,

Dannon Co. Promotes Healthy Life

By Beth L. Jokinen, The Lima News, Ohio

Jul. 17–MINSTER — In its third year of giving money to promote healthy lifestyles in today’s youth, the Dannon Co. is seeing results.

Pupils at Minster schools, the first recipient, are choosing more salads and fruits at lunch. They are more physically active and their families are joining the local YMCA.

Dannon touted the success Wednesday as it awarded its third $30,000 Next Generation Nutrition Grant to the Council on Rural Services.

“We feel we have a special mission with our youth,” Didier Menu, senior director of the Minster Dannon plant, said during a check-presentation ceremony Wednesday.

The nonprofit organization, which works in 10 counties, will use the funds for its childhood nutrition awareness program, In the Know. It will work with schools, dieticians, local health departments and the YMCA in Auglaize, Shelby and Darke counties to encourage 900 children, parents and community members to maintain healthy lifestyles.

Jeanine Bensman, infant and toddler program manager, said the money will specifically be used for training to help raise awareness among staff, parents and others on proper nutrition and exercise.

“If we are modeling for them [children], and we are truly being advocates for healthy choices, then I feel like we will be making a difference,” she said.

The council will also purchase materials with the grant money.

This is the third Next Generation Nutrition Grant to be awarded in Auglaize County. Each Dannon plant awards grants to local projects, totaling $340,000.

State Sen. Keith Faber, R-Celina, thanked the company for being a good corporate citizen, adding that the grant and its impact in communities, goes above and beyond. Promoting good health makes his job easier too, he added.

“It is going to be so much easier for the state, when we deal with budget issues, if I don’t have to worry about long-term health issues,” he said. “It is much easier to deal with a healthy population than it is to deal with an unhealthy population.”

You can comment on this story

at www.limaohio.com.

—–

To see more of The Lima News or to subscribe to the newspaper, go to http://www.limanews.com.

Copyright (c) 2008, The Lima News, Ohio

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

NASDAQ-OTCBB:GDNNY,

Converting Nursing Homes into Lively Edens

By Helen Dennis

Question: I have been visiting a 98-year old friend in a nursing home. Her care is generally good. What I do know is that I do not want to live my last years or months in such a place. What can I look forward to? I am 72 years old.

–B.L.

Dear B.L.:

You have asked a question that worries many.

Few, if any, of us consider a nursing home our desired destination point. Yet, there are times when a nursing home is necessary, since there are few options available – at least today.

A nursing home is appropriate for those who require 24-hour nursing care and cannot be cared for at home.

This type of facility provides the greatest degree of medical care. Each patient/resident is under the supervision of a physician and an onsite registered nurse 24 hours a day, seven days a week.

Cost can be an issue. The American Association for Homes and Services to the Aging reports as of April, the daily average cost for a private room in a nursing home is $213, or $77,745 annually. A semiprivate room is $189, or $68,985 annually.

Our country is facing a national challenge. We know that approximately half of those 85 and older are suffering from, or will suffer from, Alzheimer’s disease. During the later stages of the disease, most Alzheimer’s victims require 24-hour care.

From 2007 to 2015, the number of Americans 85 and older is expected to increase by 40 percent. And in 2031, the first wave of the 76 million boomers will turn 85. Unless there is a cure or protocol for prevention, we are not equipped to respond to what will be an overwhelming need for care.

Enter the Eden Alternative developed by Dr. William H. Thomas and described in his book, “Life Worth Living: How Someone You Love Can Still Enjoy Life in a Nursing Home” (VanderWyk & Burnham, 1996).

Thomas is a crusader determined to revolutionize the nursing- home industry. His vision is to convert nursing-home environments into habitats for human beings rather than facilities for the frail and elderly.

According to Thomas, the Eden Alternative is a way to create a vigorous and vibrant habitat – filled with plants, outdoor gardens, birds and children, care and companionship.

In 1991, he transformed the first nursing home in New Berlin, N.Y. It had more than 80 parakeets, 10 finches, two lovebirds, a half-dozen cockatiels and two canaries. All parakeets were adopted by residents and staff and each had a name.

Thomas and his team replaced lawns with gardens of flowers and vegetables. Crops were harvested. Fresh flowers and plants were placed indoors.

He believes that we all have a stake in tilling the soil; that a culture of domestic animals and edible plants is possibly the oldest, most common denominator that connects one person to another.

Children became part of the fabric of daily life. After-school programs were developed serving children from the community and residents. Students from a nearby school helped care for the plants and animals and kept a diary as a school assignment.

The Eden Alternative is based on 10 principles:

Loneliness, helplessness and boredom are plagues and account for most of the suffering among elders.

An elder-centered community is committed to a human habitat where life revolves around contact with plants, animals and children.

Loving companions are the antidote to loneliness.

An elder-centered community creates opportunity to give and receive.

The community creates an environment where the unexpected can happen; it is an antidote to boredom.

The opportunity to find something meaningful is essential to human health.

Medical treatment should be the servant, not the master, of human caring.

The community honors its elders by de-emphasizing top-down bureaucratic authority, placing decision-making with the elders or those closest to them.

Creating an elder-centered community is a process, not a program.

Wise leadership is the lifeblood against the plagues of loneliness, helplessness and boredom.

The evaluation of the Eden Alternative was positive. Compared to a traditional facility, residents needed significantly fewer drugs and lived longer, and staff turnover was less.

In California, there are 12 registered Eden Alternatives. The closest one to the South Bay is in La Jolla.

Thomas did not stop with the Eden Alternative. His most recent concept is the Green House, a radically new approach to long-term care. I’ll discuss that next week.

Helen Dennis is a specialist in aging, with academic, corporate and nonprofit experience. Send her your questions and concerns in care of the Daily Breeze, 5215 Torrance Blvd., Torrance, CA 90503- 4077; or fax to 310-540-7581, or e-mail to [email protected].

(c) 2008 Daily Breeze. Provided by ProQuest Information and Learning. All rights Reserved.

Hospital Operator to Merge Divisions: Bon Secours Virginia Will Arise From Richmond, Hampton Roads Units

By John Reid Blackwell, Richmond Times-Dispatch, Va.

Jul. 17–Bon Secours Health System Inc. is bringing all of its Virginia operations under one umbrella.

The not-for-profit hospital operator said it is combining its two local divisions in Virginia — Bon Secours RichBREAKING NEWS 7/16/08 6:58 AM on inRich.commond and Bon Secours Hampton Roads — into a single unit called Bon Secours Virginia.

The combination is aimed at helping Bon Secours standardize services such as computerized record-keeping at its Virginia operations, but it is not expected to result in major employment changes. The divisions already share some functions, such as billing.

“Nationally, there is a trend toward integrated health systems, and this is largely a response to that trend,” said Michael Spine, Bon Secours’ senior vice president of business development. “As we work with our doctors, we find more and more that we are able to standardize our services, so we can offer consistency across our facilities.

“We anticipate growth in the next few years,” Spine said. “I would say it will have a net positive impact on employment.”

The merger does mean some management changes. Peter J. Bernard, senior vice president and chief executive officer of Bon Secours Richmond, keeps the local CEO job and adds that of chief executive of Bon Secours Virginia.

Michael Kerner, executive vice president and administrator at St. Mary’s Hospital in Henrico County, will become CEO of Bon Secours Hampton Roads, effective Aug. 4. He will report to Bernard. Bon Secours said it expects to fill the position at St. Mary’s by Sept. 1.

Another major hospital owner in Virginia, HCA, recently announced that it was consolidating operations in the state into one division. The nation’s largest for-profit hospital operator combined its Capital and Richmond divisions, which includes six Richmond-area hospitals and numerous outpatient centers, as well as hospitals in Northern Virginia and Southwest Virginia and in New Hampshire, Kentucky and Indiana.

About 6,600 people work at Bon Secours Richmond-area operations, which encompass four hospitals: St. Mary’s Hospital, Memorial Regional Medical Center in Hanover County, Richmond Community Hospital in Richmond, and St. Francis Medical Center in Chesterfield County. The division also includes Bon Secours HealthSource, which is made up of more than 20 facilities, including physician practices, home-care services and assisted-living facilities.

Bon Secours Hampton Roads, with about 4,100 employees, consists of DePaul Medical Center in Norfolk, Maryview Medical Center in Portsmouth and Mary Immaculate Hospital in Newport News.

Richard A. Hanson, chief executive officer of Bon Secours Hampton Roads, has been named senior vice president of performance management at Bon Secours Health System, which also has hospitals in Maryland, Kentucky, South Carolina and New York. Contact John Reid Blackwell at (804) 775-8123 or [email protected].

—–

To see more of the Richmond Times-Dispatch, or to subscribe to the newspaper, go to http://www.timesdispatch.com.

Copyright (c) 2008, Richmond Times-Dispatch, Va.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

NYF-Type Pegmatite

By Rakovan, John

The very first Word to the Wise column dealt with the term pegmatite (Rakovan 2003). This was especially fitting because pegmatites are one of the most important rock types or geologic environments for the production of beautiful and interesting mineral specimens. A qualitative assessment of this can be made through a simple review of mineral journals, where one finds that tourmaline, aquamarine (often referred to as t&a), and other pegmatite minerals comprise a large proportion of cover images. Pegmatites were described in a few short paragraphs in that first column, yet the number of papers and books that have been written about them is huge. Although most pegmatites are granitic, there are still many differences among them that have led to classifications of this one rock type based on characteristics such as style of formation, timing of formation relative to their host rocks, depth of formation, magmatic source, internal structure, minor element chemistry, and so forth. One of the most widely used classification schemes is that of Cerny (1991). In it, pegmatites are classified by their depth of emplacement (proposed by Buddington 1959; modified by Ginsburg, Timofoyev, and Feldman 1979) and are further divided into subclasses, types and subtypes based on geochemical features, mineral assemblages, and textural attributes that reflect the pressure and temperature conditions present during solidification. The degree to which each of the classes is subdivided is a function of the variability present and our current knowledge. Thus, modifications to Cerny (1991) have been suggested as our knowledge of pegmatites has grown (e.g., Wise 1999; Pezzotta 2001; Cerny and Ercit 2005). A comprehensive review of all the different classification schemes and pegmatite types is beyond the scope of this column. However, because of its common usage (e.g., Hanson, Simmons, and Falster abstract on the Mojave County pegmatite district, Rochester Mineralogical Symposium abstracts, page 343, this issue), this column focuses on NYF-type pegmatites (Cerny 1991; Cerny and Kjellman 1999; Martin 1999; Wise 1999; Cerny and Ercit 2005; Simmons et al. 2003; Simmons 2007). NYF stands for niobium (Nb), yttrium (Y), and fluorine (F), rare elements that concentrate to the point of becoming minor constituents in the “classic” NYF pegmatites. Originally classified as the NYF family, this term is based on compositional characteristics that are related to the source (provenance) of the original magma and the chemical evolution of the magma as components are removed and others are concentrated as fractional crystallization and differentiation occur. These three elements (NYF) are the most notably enriched; however, other rare elements are also characteristically elevated in their concentration. Yttrium and the lanthanides are rare-earth elements (REE), all of which have similar geochemical behavior; consequently, NYF pegmatites are usually enriched in all of the REE. Elevated concentrations of Sc, Zr, U, and Th are also typical.

The second family of pegmatites proposed by C erny (1991), based on minor element characteristics, is the LCT type that exhibits enrichment in lithium (Li), cesium (Cs), and tantalum (Ta) as well as Rb, Be, Sn, Nb (Ta > Nb), B, P, and F, to varying degrees. An example of an LCT pegmatite is the Oceanview mine, described by Mauthner in this issue (pages 292-297). Many pegmatites fit well into this chemical classification, but as can be expected when trying to pigeon-hole the natural world, there are exceptions, including those that have characteristics of both; the result is a third family of pegmatites, the mixed NYF + LCT family.

The depth-related classes in the taxonomy of Cerny (1991) include miarolitic, rare-element, muscovite, rare-element muscovite, and abyssal in order of increasing depth (see table). Although these classes are well defined, the use of this nomenclature to describe different depth classes is unfortunate because there are terms that refer to a structural feature (miarolitic pockets), an element group (rare-element), a mineral (muscovite), and a location (abyssal). This can be confusing, especially when one is trying to keep track of other classification terms based on chemistry or other characteristics. Also, miarolitic cavities, for which the miarolitic class is named, are found in most of the other classes. Originally, NYF pegmatites were thought to be restricted to the rare-element class, but pegmatites with an NYF type of signature are now known from all classes (Ercit 2004). Geologically, another confusing aspect is that some of each type can occur in geographically close terrains but have different ages and parent magmas.

Based on geological, chemical, and isotopic data, several possible mechanisms have been proposed by which the parent magmas of NYF pegmatites may form (Cerny and Ercit 2005). However, the vast majority of those that have been studied, including the “classic NYF family” formed through magma generation in divergent tectonic settings, known as MINERALSanorogenic (not associated with mountain building) magmas (Wise 1999). In contrast, there is a strong correlation between LCT-family pegmatites and orogenic tectonic settings (compressional regimes associated with mountain building). It should be noted that although these correlations exist, there are many exceptions.

Classic examples of NYF pegmatites include those of the Pikes Peak Batholith and Mount Antero, Colorado (Henrich 1985; Raines 2001; Lees 2005; Modreski 2005); Moat Mountain and the Conway Granite, New Hampshire (Samuelson, Hollmann, and Holt 1990); Baringer Hill, Texas (Landes 1932; Francis and Lange 1999); the Sawtooth Batholith, Idaho (Menzies and Boggs 1993); Klein Spitzkoppe and the Erongo Mountains, Namibia (Cairncross 2005; Cairncross and Bahmann 2006); Baveno, Italy (Albertini 1983); Tanakamiyama, Shiga Prefecture (Obayoshi 2002; Nambu 1970); and the Naegi Granite, Gifu Prefecture, Japan (Nambu 1970; Scalisi and Cook 1983).

If this discussion seems a bit confusing, it is in part because our understanding and classification of pegmatites are evolving, and, as stated in Simmons (2007), a trend toward a petrogenetic classification, related to the tectonic regimes and the processes of magma generation, is emerging from current research. For example, Martin and De Vito (2005) attribute these NFY and LCT geochemical “fingerprints” to characteristics of the magma source and to the tectonic setting where the parental magma was generated. However, because the term NYF-type pegmatite is commonly employed today, it is useful to understand the general ideas behind it.

AKNOWLEDGMENTS

I thank Bob Cook, Terry Huizing, and Carl Francis for their reviews and helpful suggestions.

REFERENCES

Albertini, C. 1983. Famous mineral localities: Baveno, Italy. Mineralogical Record 14:157-68.

Buddington, A. F. 1959. Granite emplacement with special referance to North America. Geological Society of America Bulletin 70:671-747.

Cairncross, B. 2005. Famous mineral localities: Klein Spitzkoppe (Namibia). Mineralogical Record 36:317-35.

Cairncross, B., and U. Bahmann. 2006. Famous mineral localities: The Erongo Mountains, Namibia. Mineralogical Record 37:361-470.

Cerny, P. 1991. Rare-element granitic pegmatites. Part I: Anatomy and internal evolution of pegmatite deposits. Part 2: Regional to global environments and petrogenesis. Geoscience Canada 18:49-81.

Cerny, P., and S. Ercit. 2005. The classification of granitic pegmatites revised. Canadian Mineralogist 43:2005-26.

Cerny, P., and J. Kjellman. 1999. The NYF family of granitic pegmatites: Simplistic past, fluid present, reformed future. Canadian Mineralogist 37:799-800.

Ercit, T. S. 2004. REE-enriched granitic pegmatites. In Rare- element geochemistry and ore deposits, ed. R. L. Linnen and I. M. Samson. Geological Association of Canada Short Course Notes 17:257- 96.

Francis, C., and D. E. Lange. 1999. Baringer Hill, Llano, Texas: A classic NYF pegmatite. Canadian Mineralogist 37:818.

Ginsburg A. I., I. N. Timofeyev, and L. G. Feldman. 1979. Principles of geology of the granitic pegmatites. Nedra, Moscow, USSR. [in Russian]

Henrich, E. W. 1985. A Mount Antero postscript. Rocks & Minerals 60:14-16.

Landes, K. K. 1932. The Baringer Hill, Texas, pegmatite. American Mineralogist 17:381-90.

Lees, B. 2005. A spectacular new aquamarine find on Mount Antero, Chaffe County, Colorado. Rocks & Minerals 80:198-99.

Martin, R. F. 1999. Petrogenetic considerations: A-type granites, NYF pegmatites, and beyond. Canadian Mineralogist 37:804-5.

Martin R. F., and C. De Vito. 2005. The patterns of enrichment in felsic pegmatites ultimately depend on tectonic setting. Canadian Mineralogist 43:2027-48.

Menzies, M. A., and R. C. Boggs. 1993. Minerals of the Sawtooth Batholith, Idaho. Mineralogical Record 24:185-202.

Modreski, P. 2005. Colorado mineral collecting localities. Rocks & Minerals 80:316-32.

Nambu, M. 1970. Introduction to Japanese minerals, ed. by editorial committee for Introduction to Japanese Minerals organizing committee, International Mineralogical Association-International Association on the Genesis of Ore Deposits Meeting ’70. Geological Survey of Japan.

Obayoshi, T. 2002. Minerals of Tanakami region: Japan’s pegmatite- producing areas #1. Nakatsugawa Mineral Museum. [in Japanese] Pezzotta, F. 2001. Madagascar’s rich pegmatite districts: A general classification. In extraLapis English No. 1, Madagascar, 34-35. East Hampton, CT: Lapis International.

Raines, E. 2001. Mineral deposits of the Pikes Peak Batholith, Colorado. Rocks & Minerals 76:298-325.

Rakovan, J. 2003. Word to the Wise: Pegmatite. Rocks & Minerals 78:201.

Samuelson, P. D., K. H. Hollmann, and C. L. Holt. 1990. Minerals of the Conway and Mount Osceola granites of New Hampshire. Rocks & Minerals 65:286-96.

Scalisi, P., and D. Cook. 1983. Classic mineral localities of the world: Asia and Australia. New York: Van Nostrand Reinhold.

Simmons, S. 2007. Pegmatite genesis: Recent advances and area for future research. In Granitic pegmatites: The state of the art. Porto, Portugal. Program with abstracts.

Simmons, W., K. Webber, A. U. Falster, and J. Nizamoff. 2003. Pegmatology: Pegmatite mineralogy, petrology and petrogenesis. New Orleans, LA: Rubellite Press.

Wise, M. A. 1999. Characterization and classification of NYF- type pegmatites. Canadian Mineralogist 37:802-3.

JOHN RAKOVAN

Department of Geology

Miami University

Oxford, Ohio 45056

[email protected]

Dr. John Rakovan, an executive editor of Rocks & Minerals, is a professor of mineralogy and geochemistry at Miami University in Oxford, Ohio.

Copyright Heldref Publications Jul/Aug 2008

(c) 2008 Rocks and Minerals. Provided by ProQuest Information and Learning. All rights Reserved.

USCG Puts Semper Paratus to Test at Training Event

By David Ball, The Port Arthur News, Texas

Jul. 17–BEAUMONT — What would happen if terrorists were to attack one of our Southeast Texas ports? Or if they attacked one of our refineries? Pipeline? A tank farm?

Emergency responders do not have the luxury of dealing with the theoretical. Consequently, the United States Coast Guard put their Semper Paratus motto — Always Ready — to the test with other local agencies as they participated in the Sabine-Neches Emergency Coordination and Response Exercise this week in Beaumont.

The simulated training was in response to a multi-mode terrorist attack. The command center was headquartered at Ford Park.

Bob Stegall is the security specialist for the USCG Marine Safety Unit in Port Arthur and director of the event. He said this event has been in the planning for the last three to four years between federal, state and local agencies working together.

“We’ve had a great response from the three county judges (Jefferson, Orange and Hardin Counties) and emergency response coordinators,” Stegall said. “We’ve had over 600 city and county responders trained in incident command.”

The exercise was designed for a regulated response, to pool resources and to pool responses. Part of the pooling of resources is a statewide program where first responders can continue performing their jobs while other emergency personnel gather and look at resources to assist them.

“There are different targets readily available in the area and some vulnerabilities, but we can respond on sea and on land,” Stegall said. “We feel this is a prime target area. We train to respond and hone our abilities and capabilities and learn some lessons so we can improve.”

Some of the lessons learned at the terrorist training were gleaned from dealing with Hurricane Rita. Stegall said every third month, cities conduct emergency response team training that involves entire city staffs including city managers and city attorneys.

“They’re enthusiastic about it. They’ve seen what happened from Rita and they don’t want it to happen again,” he said.

Another component of the training is developing a common terminology and common paperwork of documentation and ordering supplies. Also, cross-training throughout the state enables responders to be called up and relieve others in emergency situations.

Stegall further said port facilities have been spot-checked up and down the Gulf Coast and the Coast Guard was “very pleased with the results and ready to go.”

The USCG has also been assisted with technological advances to utilize for security along with the awarding of port security grants for equipment such as boats, helicopters, etc.

John Owens is deputy chief of the Port Arthur Police Department and the emergency management coordinator for the city. He said regional responders responded to simultaneous events during the terrorist simulations at multiple locations in the area such as the Montage Center at Lamar University and the port of Beaumont.

The exercises worked on response, communication and recovery.

Stephen L. Curran, fire chief of Port Neches and emergency management coordinator for the city, said the multiple events ranged from Beaumont to Sabine Pass for practicing response capabilities, command and control and whatever else needed to be done.

“It’s been a friendly encounter and an efficient response. I don’t think any agencies have worked better together in the entire state of Texas,” Curran said.

—–

To see more of The Port Arthur News or to subscribe to the newspaper, go to http://www.panews.com/.

Copyright (c) 2008, The Port Arthur News, Texas

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Two Arrested After Record Cannabis Haul in Tokyo

Text of report in English by Japan’s largest news agency Kyodo

Tokyo, July 17 Kyodo – A Japanese business executive and a Chinese student have been arrested for allegedly possessing cannabis for sale and around 180 kilograms of cannabis with a street value of 720 million yen has been seized from a condominium in Tokyo, the Metropolitan Police Department said Thursday.

The amount seized was the largest ever found by police in a raid, the police said.

Hiroaki Fukui, a 40-year-old executive from Tokyo’s Edogawa Ward, and Liang Shuan, a 22-year-old Chinese student who lives in Koto Ward, are suspected of hiding the cannabis at a Tokyo condominium on July 1, while Fukui is also suspected of selling around 25 grams of amphetamine for 450,000 yen to a 42-year-old Chinese man in Yokohama on Dec. 29 last year.

Originally published by Kyodo News Service, Tokyo, in English 0230 17 Jul 08.

(c) 2008 BBC Monitoring Newsfile. Provided by ProQuest Information and Learning. All rights Reserved.

Stalking the Silent Killer

By Landless, Peter N

If you don’t stop it, it will stop you . . . dead. There are seldom symptoms. Medical professionals aren’t altogether sure what causes it. Yet hypertension (high blood pressure) is one of the world’s greatest health problems. It’s mysterious, evasive, and lethal.

High blood pressure contributes significantly to death rates through stroke, heart failure, and kidney failure. Mass health screening has helped increase recognition of the problem; and wherever patients are adequately treated, death rates from the disease drop significandy.

But consider these statistics: only 50 percent of patients who have hypertension are on dierapy of any kind. Of those, only 30 percent have their blood pressure controlled at ideal levels. Much work needs to be done in order to combat this “silent killer.”

Diagnosis

Hypertension is not diagnosed on a single reading. Pressure values should be noted on at least three separate occasions, using blood pressure devices at your doctor’s office, those do-it- yourself readers at many grocery stores, or with a simple at-home blood-pressure kit.

It’s important to note that, for some, the act of visiting a doctor can temporarily raise their blood pressure, owing to uncertainty or the fear of what may be found. This “white coat” effect may make accurate readings impossible, even if repeated. That’s why it’s important that blood pressure levels be checked when a person is as relaxed and unstressed as possible.

Where the diagnosis is in doubt or to monitor treatment efficacy, the most effective measuring mediod is ambulatory blood pressure monitoring which may be performed over a 48- to 72-hour period. Blood pressure is measured and recorded on a recording device at intervals throughout the day and night, collecting an accurate reflection of blood pressures away from the stress of the clinic/ office/ hospital environment.

Cause

Despite advances in treatment, relatively little is known about the cause of hypertension. In 90 percent of patients, absolutely no cause is uncovered. This condition is called “primary” or “essential” hypertension. It’s common to find hypertension occurring in families, suggesting genetic factors. The incidence of hypertension also increases with age.

Physiology of Blood Pressure

The human heart muscle is constantly in one of two states: contracted (systole) which forces blood out of the heart and sends it coursing throughout the body, and relaxed (diastole) which allows replacement blood to enter the heart chambers, ready to be sent on its life-sustaining journey. This pumping action continues unabated until the day we die.

Normal blood pressure reading is 120/80 mm Hg (millimeter of mercury). That means die systolic pressure is at 120 mm Hg, and the diastolic reading hovers at 80.

The Creator has put in place some amazing checks and balances to keep our circulatory system operating properly. When blood pressure falls, the kidneys release the enzyme rerun into the bloodstream. Rerun splits the inactive angiotensinogen (a large protein that circulates in the bloodstream) into pieces. One piece is angiotensin I which is men split by the angiotensin-converting enzyme (ACE) forming angiotensin II-a very powerful constrictor of small arteries, thus raising the blood pressure.

Angiotensin II also triggers the release of another hormone called aldosterone from the adrenal glands. This causes the kidneys to retain sodium and eliminate potassium. The retained sodium brings about water retention, which increases the blood volume and, consequently, blood pressure.

This amazing reninangiotensinaldosterone system (RAAS) was designed by God to regulate blood pressure and keep the internal environment of our bodies constant. It’s a beautiful demonstration of how “fearfully and wonderfully” we’re made. It’s no wonder that David cried out, “Your works are wonderful, I know that full well” (Psalm 139:14).

Unfortunately, this is the very system that becomes disturbed when individuals with a tendency to high blood pressure take in excessive salt in their diet. On the upside, it’s also the target of specific “designer” medications used with good success in the treatment of hypertension.

Environmental Factors

Lifestyle choices play a leading role in both the development and control of hypertension. Perhaps, even today, you did something that can cause or aggravate the disease. If you’re a smoker, are obese, consume alcohol, lead a sedentary life, include copious amounts of salt in your diet (processed or prepackaged foods are prime suppliers), or have a sugar intolerance that’s leading you into diabetes, you may also be suffering from hypertension. Like I said before, you probably aren’t even aware of the fact that you’ve become a ticking time bomb.

Secondary hypertension

Five percent of hypertensive patients have an associated disease or condition, which, by default, raises blood pressure. These include problems with the kidneys, the endocrine system (which creates hormonal controls), nervous system disorders, and chronic stress.

As mentioned, alcohol wreaks havoc on the body, as do some nonsteroidal anti-inflammatory medications on the kidneys. Pregnancy can be complicated by elevated blood pressure as well.

Complications

Hypertension affects a number of bodily systems, some profoundly. It’s in these complications where the silent killer’s face is clearly seen.

Arteries: Uncontrolled hypertension accelerates atherosclerosis (degeneration and hardening of the arteries) and further increases the risk of potentially deadly aneurysm formation. An aneurysm is a weakness of the arterial wall, which creates a bulge, like a balloon. If this aneurysm bursts in the aorta or brain, the results can be catastrophic, quickly generating permanent damage or death. It’s possible for the circulatory system to lose all of its blood supply through an aneurysm, filling the body cavity like a broken dam fills a valley. Death swiftly follows.

Brain: Hypertension can cause strokes, either by causing clotting in the small arteries of the brain, or creating a “bleed out” into the brain.

Heart: Chronic high blood pressure accelerates the disease process in the coronary arteries and places undue strain on the heart muscle itself, making it thicken and eventually lose its flexibility and ability to function adequately. Heart failure follows. Regular, even strenuous exercise generally does not thicken the heart muscle in this way.

Kidneys: Increased blood pressure damages the delicate filtration units of the kidney, leading, ultimately, to kidney failure.

Eyes: Hypertension can damage the small blood vessels of the retina of the eye. If the pressure is extremely high and uncontrolled, it can lead to visual disturbance.

Understanding the Readings

The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure monitors and studies the trends in hypertension treatment and outcomes. Here are its most recent recommendations:

Normal blood pressure:

* Systolic 120 mm Hg

* Diastolic 80 mm Hg

Even when blood pressure readings are normal, risk factor monitoring is needed and healthy lifestyle encouraged.

Prehypertension:

* Systolic 120 – 139 mm Hg

* Diastolic 80 – 89 mm Hg

This may be regarded as the early stage of hypertension. Lifestyle modification is essential to prevent it from worsening and developing complications.

Stage 1 hypertension:

* Systolic 140 – 159 mm Hg

* Diastolic 90 – 99 mm Hg

Patients who have these readings require immediate lifestyle modification, plus the use of medication, which is introduced gradually as a doctor monitors the response and any possible side effects, until the blood pressure is back to normal range (120/80 or less).

Stage 2 hypertension:

* Systolic greater than 160 mm Hg

* Diastolic greater than 100 mm Hg

At this level of hypertension, lifestyle modification is vital. In addition, the evidence of multicenter studies of many thousands of patients (as recorded in scientific literature) shows that it’s most likely that the patient will require treatment with at least two different medications.

Educating yourself about the disease and its complications could save your life. But along with education must come compliance. If you have hypertension, you must adhere to the lifestyle modification and take the prescribed medication as directed. To do otherwise is allowing the silent killer full access to your future.

Treatment

There are two approaches to the treatment of hypertension, both vital to success. In most cases, to do one without the other raises the risk that the disease won’t be conquered.

The first is nondrug treatment and is essential in all cases of high blood pressure. The list is short but very, very powerful.

1. Stop smoking completely and permanently. I cannot emphasize this enough. Smoking is the most damaging thing you can do to your body and undoubtedly causes premature death.

2. Stop alcohol consumption.

3. Exercise daily. If you’ve been sedentary up until now, begin with 30 minutes of exercise per day. Then build up to 45-90 minutes daily.

Walking is one of the best ways to lower your risk of most diseases including diabetes and cancer. A brisk, daily walk is good for your body, mind, and relationship with God, especially if you invite Him to come along. 4. Restrict salt intake. Excessive salt in the diet increases water retention, which increases blood volume, which raises blood pressure. Most highly processed and prepackaged foods contain an incredible amount of salt and can quickly aggravate hypertension (see sidebar).

5. Increase fruits and vegetables in your diet.

6. Learn to manage your stress. Ask yourself, “Is this project, or job, or concern worth dying for?” A good stress-management seminar or Bible-based book on the subject can mean the difference between life and death for many… perhaps even you. And never underestimate the power of personal, from-the-heart prayer.

Diet to the Rescue

The best eating plan for improving blood pressure was confirmed in the Dietary Approach to Stop Hypertension (DASH) study. It’s based on the large multicenter study that showed, conclusively, that a certain diet is most effective in the control and prevention of hypertension. The DASH diet includes the following components:

1. It’s low in saturated fats and total fat. A plant-based diet assures the right amount-and the right kinds-of fats.

2. It contains eight to 10 servings of fruits and vegetables per day. The potassium in fruits and vegetables is particularly important in this instance. Fiber is healthy too.

3. It’s low in salt (sodium chloride). The latest recommendation is 1,500 milligrams per day for patients with hypertension. We need much less salt than we think we do.

New Developments

Lifestyle interventions retain their absolute importance in the prevention and management of hypertension. But in those cases where genetics plays a more stubborn role, new medications are being developed that will also work in partnership with lifestyle changes and minimize the unwanted side effects associated with drug therapy.

A fascinating-but still experimental-approach, which is being studied, is targeting specific components of the RAAS with a vaccine. This offers the potential of reducing-or even eliminating- the need for medications altogether. However, this approach requires long-term study to identify any side effects and assure safety.

In some cases, individuals with high blood pressure have been able to improve their condition with lifestyle choices and supplemental medications to the point where medications are no longer needed or where doses may be reduced. It’s important that you work with your doctor before attempting to alter any prescribed drug therapy. He or she will monitor your progress and help you find the right balance that will keep you safe and healthy.

Conclusion

Hypertension is a lifelong problem that requires lifelong treatment. There’s no doubt that lifestyle changes, as described, are essential. For most patients, medication is required as well. Since medications have side effects, the patient must be professionally helped to find the treatment that’s best tolerated.

There are many types of medications, and a “recipe” that suits each individual patient and their economic circumstances can be crafted. It’s important to remember that the only treatment that works is the one that you follow.

Many outcomes in common diseases such as hypertension, heart failure, and coronary heart disease are influenced by choices; the choice to eat healthfully, to exercise, to be active in lifestyle interventions, and to take appropriate medications when needed.

When it comes to health, once you know what needs to be done, you need to follow Nike’s example and “Just do it!” The “silent killer” is stalking you. With what you now know, you can begin to fight back today!

Hypertension is not diagnosed on a single reading. Pressure values should be noted on at least three separate occasions.

HOW MUCH SALT DO YOU NEED?

The human body needs only about ? ,000 milligrams (1 gram) of salt per day. That requirement can easily be met by eating only foods “as grown.” The typical American diet, however, provides in excess of 10,000 milligrams (10 grams) of salt per day. This means that people consume 10 times more salt than their body needs to function well.

Salt is sodium chloride. Food labels list sodium rather than salt content. When reading a nutrition facts panel on a food product, look for the sodium content. Foods that are low in sodium are low in salt.

The Food and Drug Administration recommends that we consume less than 2,300 milligrams of sodium (approximately 1 teaspoon of salt) per day. Individuals with hypertension, African-Americans, and middle-aged and older adults should aim to consume no more than 1,500 mg of sodium (approximately /4 teaspoon of salt) per day. Source: Health Power

Dr. Peter Landless, a cardiologist, is the executive director of the International Commission for the Prevention of Alcoholism and Drug Dependency (ICPA) and an associate director in the General Conference Health Ministries Department of the Seventh-day Adventist Church. Originally from South Africa, he’s been actively involved in medical mission work his entire career.

Copyright Vibrant Life Jul/Aug 2008

(c) 2008 Vibrant Life. Provided by ProQuest Information and Learning. All rights Reserved.

The Dope on the DEA

Regarding Bill Steigerwald’s column about the U.S. Drug Enforcement Administration’s 35th birthday (“35 years of drug war failure,” July 13 and PghTrib.com), the primary hiring criterion for DEA agents is ignorance.

The emphasis on “drug-free” backgrounds ensures that those least knowledgeable about the use and effects of illegal drugs are charged with enforcing laws against them.

There is a good reason millions of Americans prefer marijuana to martinis.

Anyone who has experimented with both drugs knows that alcohol is far more dangerous. Alcohol drinkers who overindulge risk painful hangovers, loss of control over bodily functions, even death.

Compared to legal drugs like alcohol and prescription narcotics, marijuana is relatively harmless. It is not possible to consume enough marijuana to die from an overdose. Not even aspirin can make the same claim.

Marijuana can be harmful if abused, but criminal records are inappropriate as health interventions and ineffective as deterrents. The drug war is a cultural inquisition, not a public health campaign.

Robert Sharpe

Washington, D.C.

The writer is a policy analyst for Common Sense for Drug Policy.

(c) 2008 Tribune-Review/Pittsburgh Tribune-Review. Provided by ProQuest Information and Learning. All rights Reserved.

Southridge LeGrand Hair Salon Now Offering Massage

By Ben Calwell

[email protected] 348-5188

Beauty and health now go hand in hand at the LeGrand Hair Salon in the Southridge Center.

In addition to hair care, LeGrand’s Southridge customers can now experience the health benefits of therapeutic massage.

LeGrand shop Manager Cindy DeBord, a hairstylist and licensed massage therapist, offers an array of massage techniques to clients that include Swedish massage, deep tissue massage, hot stone massage, chair massage, facials and foot reflexology.

Clients can opt for a chair massage, fully clothed, or the more traditional massages on a specially designed bed in a private room.

“If somebody doesn’t want a full body massage, we have a chair massage, where they don’t have to de-robe. A lot of people want you to work on their necks, shoulders and arms,” DeBord said.

The chair massages “are quick and affordable,” she said.

For the table massages, clients can go in for a 30-minute session or a one-hour session.

“I also do facials, which goes with my cosmetology license.”

DeBord said she enjoys practicing foot reflexology, which provides relief for tired and aching feet.

“It’s facials for tired feet,” she said.

Foot reflexology involves foot massage and thumb pressure and includes a “sea salt exfoliation,” which helps get rid of dead skin.

It ends with a relaxing foot and leg massage.

“You’re getting the massage from the knee down – it works the calves, the legs and the feet. There’s a lot of benefits to reflexology,” she said.

DeBord said massage is growing in popularity, with doctors and chiropractors incorporating the service into their practices.

DeBord became interested in massage through a friend.

“We would sneak away to Stonewall Resort and get massages and facials, and I thought, ‘I could do this.'”

Combining her massage skills with her 20-plus years experience as a hairstylist, allows DeBord to treat the whole person.

Massage, she said, “is a passion that I have. I can make them look good and feel good. It’s another service that I can offer.”

Since introducing massage at LeGrand, DeBord said most customers have been opting for full massages.

And they have the option of getting “hot stone” massages that incorporate heated, basalt stones that, once they are cooled to the proper temperature, are placed on the body.

DeBord is finding that people these days are more knowledgeable about their health and view massage as being good for them mentally and physically.

“People are more educated about their health, and they’re more conscious of being healthy,” she said.

Swedish massage focuses on relaxation and uses long, fluid strokes and gentle kneading techniques. The cost is $35 for 30 minutes, $65 for one hour.

Deep Tissue massage aims to release chronic tension in the body and focuses on specific areas. The cost is $35 for 30 minutes, $65 for one hour.

Hot Stone massage combines heated stones and Swedish massage to soothe and comfort the muscles. The cost for this massage is $85 for one hour.

Chair Massage concentrates on tense areas of the neck, shoulders, arms and back. Fifteen minutes costs $17.50; a 30-minute chair massage costs $30.

Facials help to maintain healthy skin. Choose from cleansing, peel or exfoliating. Face, shoulders and neck massage also performed. The cost is $55 for one hour.

Foot Reflexology incorporates foot and leg massage and exfoliation and costs $55 for a one-hour session.

LeGrand Salon at the Southridge Center is open from 9 a.m. to 8 p.m. Monday through Friday, from 9 a.m. to 5 p.m. on Saturday and from noon to 5 p.m. on Sunday.

For more information, call 744-1881.

(c) 2008 Charleston Gazette, The. Provided by ProQuest Information and Learning. All rights Reserved.

Tattoos Linked to Personality Disorder

The presence of tattoos on psychiatric inpatients should alert doctors to a possible diagnosis of Antisocial Personality Disorder, U.S. researchers said.

Lead researcher Dr. William Cardasis of the Michigan Center for Forensic Psychiatry said that Antisocial Personality Disorder is a mental disorder characterized by several psychological and behavioral phenomena, including a lack of empathy and remorse, a low tolerance for anxiety and shallowness.

To be diagnosed with Antisocial Personality Disorder, the individual must have developed this behavior before the age of 15, and as such is qualitatively different from the idea of a scheming, dishonest business person or politician, unless the behavior began earlier in life, Cardasis said.

Cardasis said that of the patients studied, 15 had tattoos and 17 were diagnosed as having Antisocial Personality Disorder. Of those with tattoos, 11 of 15, or 73 percent, had Antisocial Personality Disorder, but only six of 21, or 29 percent, of those without tattoos had the same diagnosis.

The study, published in the Journal Personality and Mental Health, also uncovered an increased likelihood for those with tattoos to have previously suffered from sexual abuse, abused substances or to have attempted suicide.

AHF Treatment Proposal Accepted By US Senate

AIDS Healthcare Foundation (AHF) (www.aidshealth.org), which provides AIDS care and treatment services to more than 79,000 individuals in 20 countries worldwide, applauded the U.S. Senate for passing the legislation (vote: 80/16) re-authorizing PEPFAR (the President’s Emergency Plan for AIDS Relief), the successful US global AIDS program. AHF lauded the Senate for prioritizing lifesaving treatment through its restoration of a provision in the current law that more than half of the funding be spent on treatment. The agreement will also make it possible for as many as five million people worldwide to access antiretroviral treatment over the next five years via PEPFAR-backed programs. Currently, less than two million people are receiving treatment through PEPFAR.

“It is no exaggeration to say that millions of additional lives of people living with HIV/AIDS around the world will now be saved thanks to the actions of Congress today and we thank those courageous legislators and staffers who supported AHF’s efforts and worked so hard to make this happen,” said Michael Weinstein, President, AIDS Healthcare Foundation. “AHF worked tirelessly over the past several months to try and persuade legislators to restore the treatment focus in PEPFAR. We brought two delegations of AHF doctors and AIDS patients from Africa to Washington as part of an intense advocacy effort on the importance of treatment as the primary focus of PEPFAR. Together, we had more than 70 meetings in Senate offices with staffers and Senators, and we were able to persuade them of the critical importance of retaining the priority on treatment in the original PEPFAR legislation–something that has been key to the success of President Bush’s landmark legislation over the past five years. This is a monumental day for those living with HIV/AIDS around the world–it will literally bring new life to millions–and a landmark day for the legislators involved as well as for US foreign policy efforts.”

“We are grateful to those legislators who worked diligently to maintain the priority on treatment in PEPFAR. AHF considers this a great achievement, because it confirms that treatment is–and should be–the prime focus of PEPFAR, and the key to controlling the epidemic,” said Tom Myers, AHF’s Chief of Public Affairs. “Putting people on treatment has a multiplier effect. One person on treatment is not just one life saved, it is also one partner who is not infected. For each woman receiving treatment, that can also mean a number of children born without HIV/AIDS, and a number of children who are not made orphans.”

In May, AHF brought two delegations of AIDS medical care providers and AIDS treatment clients from Uganda, South Africa and Rwanda to Washington, DC for a series of meetings on Capitol Hill with Senate leaders to tell their personal stories of living with, or treating those with HIV/AIDS, to Congress as they considered the bill to reauthorize PEPFAR. The groups, all of whom were treatment clients or medical providers of AHF, pressed Congress to reinstate the requirement that a minimum percentage of PEPFAR funding be required to be spent on lifesaving treatment, and to increase the overall goal of those on treatment through the program.

The second African AIDS delegation also joined a number of US Senators including Senator Tom Coburn, M.D., (R-OK) and Richard Burr (R-NC) in a press conference on May 13th to call for the preservation of a focus on AIDS treatment in the PEPFAR bill.

A few Republican Senators were opposed to the $50 billion funding level; however, several of these same Senators spoke to the impact that AIDS Healthcare Foundation’s African delegations had on their impressions of the bill and the Senate compromise that was ultimately reached on maintaining a priority on treatment, which both Senator Sessions and Senator Bunning supported.

While speaking on the Senate floor about the bill this afternoon, Senator Jeff Sessions (R-AL) said, “I met with a group from Africa who urged us to oppose the legislation as originally written because it altered the requirement that medical treatment be a significant component in the bill and some other problems they had with it. They said, in fact, they said — we should oppose the bill even though they would, in many ways, benefit. We had a grandmother there whose daughter died with AIDS and she had her granddaughter there, her granddaughter was infected with H.I.V. so it was an emotional moment.”

Senator Jim Bunning (R-KY) also spoke earlier about the impact AHF’s African delegation had on his support for maintaining a treatment focus in PEPFAR. In his floor remarks, Bunning noted, “Two months ago, I had the opportunity to meet with several doctors and patients from Uganda. Through their firsthand account, I could see how PEPFAR dollars, when used wisely, can combat the spread of AIDS and be used to provide lifesaving treatment.

One of the women I met with told me how PEPFAR saved her life. Through the program, she was able to treat this deadly disease in a way that enabled her to live a normal life. She now has a job and provides for her four children. In speaking with her, I was not only struck by her conviction for life but her insistence that I continue to work to strengthen the reauthorization of PEPFAR. Like me, she knew the changes made to the program could severely weaken its effectiveness and jeopardize its future success.

This woman is a living example of how PEPFAR can be successful if implemented as the program originally intended. Through her conviction, I, along with several of my colleagues on this side of the aisle, worked to fix this bill. We were able to make some improvements, such as restoring a treatment mandate that is still lower than the current program levels–but many problems still exist.”

As part of its advocacy around PEPFAR, AHF also mounted its AIDS portrait exhibit titled, “AfricAlive: Portraits of Success,” in the Rotunda of the Russell Senate Office Building during the week of May 12-16. The traveling exhibit is a series of photographic portraits of Africans with HIV/AIDS who are alive thanks to their access to antiretroviral treatment. The venue afforded many Senators and staffers the chance to see the moving, life-sized portraits of Africans who are alive today thanks to antiretroviral treatment up close as they traveled back and forth between their Senate offices and the Capitol Building.

One of the AfricAlive portrait subjects, Fundiswa Doncabe, an AIDS treatment client from AHF’s Ithembalabantu (Zulu for “people’s hope”) clinic in Durban, South Africa, was part of the second African delegation visiting Congress. In mid-May, she traveled to Washington with her 4 year-old son, Thubelihle Shabalala, to tell her personal story of living successfully with AIDS thanks to her access to lifesaving antiretroviral treatment (ART).

PEPFAR was the result of President Bush’s groundbreaking 2003 State of the Union pledge to bring two million HIV positive Africans and others into treatment and prevent seven million new HIV infections via a five-year, $15 billion US-funded program. It currently operates in 15 focus countries and claims to support antiretroviral treatment for 1.4 million people worldwide. PEPFAR has been one of the most successful global humanitarian programs in recent memory, providing medical care to millions of people with HIV/AIDS, it has given hope to the 33 million people with HIV/AIDS in the world.

About AHF

AIDS Healthcare Foundation (AHF) is the nation’s largest non-profit HIV/AIDS healthcare provider. AHF currently provides medical care and/or services to more than 79,000 individuals in 20 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at www.aidshealth.org.

 WHAT: Media Availability Senate Re-authorizes PEPFAR, US' Global AIDS Bill, and Restores Crucial Treatment Funding Requirement, Key to Program's Success to Date. PEPFAR will save five million lives over next five years.  WHEN: Wednesday, July 16th 2008 all day  WHO:  Michael Weinstein, AIDS Healthcare Foundation President +1.323.860.5300 work +1.323.810.1238 mobile Tom Myers, AHF Chief of Public Affairs +1.323.860.5259 mobile  NOTE: We can also arrange for media to speak with one of our global medical care providers or treatment patients in Africa, Latin America or the Asia Pacific Region. Please call Ged Kenslea, AHF Communications Director at +1.323.860.5225 work or +1.323.791.5526 mobile to arrange.